TW201835083A - 雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用 - Google Patents
雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用 Download PDFInfo
- Publication number
- TW201835083A TW201835083A TW107109077A TW107109077A TW201835083A TW 201835083 A TW201835083 A TW 201835083A TW 107109077 A TW107109077 A TW 107109077A TW 107109077 A TW107109077 A TW 107109077A TW 201835083 A TW201835083 A TW 201835083A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- racemate
- heterocyclyl
- tautomer
- mixture
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title abstract description 19
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical class NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 title abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 37
- 125000001424 substituent group Chemical group 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 189
- 239000000203 mixture Substances 0.000 claims description 75
- 125000000623 heterocyclic group Chemical group 0.000 claims description 61
- -1 cyano, amino Chemical group 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 47
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 37
- 150000002367 halogens Chemical class 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 125000001188 haloalkyl group Chemical group 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 230000001668 ameliorated effect Effects 0.000 claims description 6
- 230000006399 behavior Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 5
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 5
- 206010050207 Skin fibrosis Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000029028 brain injury Diseases 0.000 claims description 5
- 208000010706 fatty liver disease Diseases 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 230000003959 neuroinflammation Effects 0.000 claims description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 5
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- ROPLCSFPUPWHGJ-UHFFFAOYSA-N hydroxycyanamide Chemical compound ONC#N ROPLCSFPUPWHGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 229940127600 A2A receptor antagonist Drugs 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 124
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
- 238000004949 mass spectrometry Methods 0.000 description 106
- 239000000243 solution Substances 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
- 238000005481 NMR spectroscopy Methods 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 54
- 230000002829 reductive effect Effects 0.000 description 52
- 239000012074 organic phase Substances 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 102000005962 receptors Human genes 0.000 description 39
- 108020003175 receptors Proteins 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000012300 argon atmosphere Substances 0.000 description 33
- 239000000706 filtrate Substances 0.000 description 33
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 32
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- 239000012065 filter cake Substances 0.000 description 27
- 229910000027 potassium carbonate Inorganic materials 0.000 description 27
- 239000007858 starting material Substances 0.000 description 26
- 239000000872 buffer Substances 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 24
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- 239000011259 mixed solution Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 17
- 238000007796 conventional method Methods 0.000 description 17
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 229960005305 adenosine Drugs 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 14
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 13
- 239000007995 HEPES buffer Substances 0.000 description 13
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000011056 potassium acetate Nutrition 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 239000012046 mixed solvent Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 10
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 9
- WPECLXUICXOZRA-UHFFFAOYSA-N 5-bromo-4-chloro-6-phenylpyrimidin-2-amine Chemical compound NC1=NC(Cl)=C(Br)C(C=2C=CC=CC=2)=N1 WPECLXUICXOZRA-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102000055025 Adenosine deaminases Human genes 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 9
- 229950005741 rolipram Drugs 0.000 description 9
- 108050000203 Adenosine receptors Proteins 0.000 description 8
- 102000009346 Adenosine receptors Human genes 0.000 description 8
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 8
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 8
- 239000001099 ammonium carbonate Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 150000007529 inorganic bases Chemical class 0.000 description 8
- 150000007530 organic bases Chemical class 0.000 description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- ZJRFNXUIBKAJRL-UHFFFAOYSA-N 7-phenyl-8-(1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C1(=CC=CC=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C=1C=NNC=1 ZJRFNXUIBKAJRL-UHFFFAOYSA-N 0.000 description 6
- IXKPSDKUKTYWJJ-UHFFFAOYSA-N 8-bromo-7-(4-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=C(C=C1)F)N)C=NN=2 IXKPSDKUKTYWJJ-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 5
- HOQAPVYOGBLGOC-UHFFFAOYSA-N 1-ethyl-9h-carbazole Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CC HOQAPVYOGBLGOC-UHFFFAOYSA-N 0.000 description 5
- HNYGPNDBPPSCBA-UHFFFAOYSA-N 5-bromo-4-chloro-6-(2,4-difluorophenyl)pyrimidin-2-amine Chemical compound BrC=1C(=NC(=NC=1C1=C(C=C(C=C1)F)F)N)Cl HNYGPNDBPPSCBA-UHFFFAOYSA-N 0.000 description 5
- KDHCZXJVJYRVEB-UHFFFAOYSA-N 7-(2,4-difluorophenyl)-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC1=C(C=CC(=C1)F)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C(F)(F)F)C KDHCZXJVJYRVEB-UHFFFAOYSA-N 0.000 description 5
- NTTBFQTZHKEVAO-UHFFFAOYSA-N 7-(4-chlorophenyl)-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=CC=C(C=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C(F)(F)F)C NTTBFQTZHKEVAO-UHFFFAOYSA-N 0.000 description 5
- MRHNBFYFTSXUGC-UHFFFAOYSA-N 8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-7-phenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=CN=2)C(F)(F)F MRHNBFYFTSXUGC-UHFFFAOYSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 208000023105 Huntington disease Diseases 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000011496 cAMP-mediated signaling Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- PTAUJBONQBKMCL-UHFFFAOYSA-N 2-[(5-bromo-2-methylsulfanyl-6-phenylpyrimidin-4-yl)amino]propan-1-ol Chemical compound BrC=1C(=NC(=NC=1C1=CC=CC=C1)SC)NC(CO)C PTAUJBONQBKMCL-UHFFFAOYSA-N 0.000 description 4
- AFGODOCBNFLECX-UHFFFAOYSA-N 5-bromo-4-(2,4-difluorophenyl)-6-hydrazinylpyrimidin-2-amine Chemical compound BrC=1C(=NC(=NC=1NN)N)C1=C(C=C(C=C1)F)F AFGODOCBNFLECX-UHFFFAOYSA-N 0.000 description 4
- ZOONJFITVKRTKB-UHFFFAOYSA-N 5-bromo-4-(2-fluorophenyl)-6-hydrazinylpyrimidin-2-amine Chemical compound BrC=1C(=NC(=NC=1NN)N)C1=C(C=CC=C1)F ZOONJFITVKRTKB-UHFFFAOYSA-N 0.000 description 4
- BKXSXLRWQZBYQO-UHFFFAOYSA-N 5-bromo-4-chloro-6-(4-fluorophenyl)pyrimidin-2-amine Chemical compound Nc1nc(Cl)c(Br)c(n1)-c1ccc(F)cc1 BKXSXLRWQZBYQO-UHFFFAOYSA-N 0.000 description 4
- ZGEDUFUHGOFADQ-UHFFFAOYSA-N 7-(4-chlorophenyl)-8-[2-(difluoromethyl)-6-methylpyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=CC=C(C=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)C(F)F ZGEDUFUHGOFADQ-UHFFFAOYSA-N 0.000 description 4
- WPCLJWGYJFOUCY-UHFFFAOYSA-N 8-[2-(difluoromethyl)-6-methylpyridin-4-yl]-7-(2-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC(C1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=C(C=CC=C1)F)N)C=NN=2)C)F WPCLJWGYJFOUCY-UHFFFAOYSA-N 0.000 description 4
- WMGQCOZRHSFECW-UHFFFAOYSA-N 8-bromo-2-methyl-5-methylsulfanyl-7-phenyl-2,3-dihydroimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)SC)CC(N=2)C WMGQCOZRHSFECW-UHFFFAOYSA-N 0.000 description 4
- FTVSTQDSSUSSGB-UHFFFAOYSA-N 8-bromo-2-methyl-5-methylsulfanyl-7-phenylimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)SC)C=C(N=2)C FTVSTQDSSUSSGB-UHFFFAOYSA-N 0.000 description 4
- ALCWFNXRZKJBIK-UHFFFAOYSA-N 8-bromo-2-methyl-5-methylsulfonyl-7-phenylimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)S(=O)(=O)C)C=C(N=2)C ALCWFNXRZKJBIK-UHFFFAOYSA-N 0.000 description 4
- OCSHIJMAAPCSIZ-UHFFFAOYSA-N 8-bromo-7-phenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=CN=2 OCSHIJMAAPCSIZ-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012053 oil suspension Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 3
- OXTVBHDILDPYAS-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 OXTVBHDILDPYAS-UHFFFAOYSA-N 0.000 description 3
- IOCZBRSURXDTNZ-UHFFFAOYSA-N 1-methyl-4-[(6-methylpyridin-2-yl)methyl]piperazine Chemical compound C1CN(C)CCN1CC1=CC=CC(C)=N1 IOCZBRSURXDTNZ-UHFFFAOYSA-N 0.000 description 3
- KWSIQJUNYMMCTB-UHFFFAOYSA-N 2-[[4-[carboxymethyl-(4-methoxyphenyl)sulfonylamino]naphthalen-1-yl]-(4-methoxyphenyl)sulfonylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CC(O)=O)C(C1=CC=CC=C11)=CC=C1N(CC(O)=O)S(=O)(=O)C1=CC=C(OC)C=C1 KWSIQJUNYMMCTB-UHFFFAOYSA-N 0.000 description 3
- SFSXNVBMAODLGN-UHFFFAOYSA-N 2-ethyl-6-methylpyridine Chemical compound CCC1=CC=CC(C)=N1 SFSXNVBMAODLGN-UHFFFAOYSA-N 0.000 description 3
- UUTMXCYCFJHKOB-UHFFFAOYSA-N 2-methylsulfanyl-6-phenylpyrimidin-4-amine Chemical compound CSC1=NC(N)=CC(C=2C=CC=CC=2)=N1 UUTMXCYCFJHKOB-UHFFFAOYSA-N 0.000 description 3
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 3
- CHZSEHFVZQLLRS-UHFFFAOYSA-N 3-methyl-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NN=C2N1C(=NC(=C2C1=CC(=NC(=C1)C(F)(F)F)C)C1=CC=CC=C1)N CHZSEHFVZQLLRS-UHFFFAOYSA-N 0.000 description 3
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 3
- XLSHDWCSQQJPRO-UHFFFAOYSA-N 4-hydrazinyl-5-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-6-phenylpyrimidin-2-amine Chemical compound N(N)C1=NC(=NC(=C1C1=CC(=NC(=C1)C(F)(F)F)C)C1=CC=CC=C1)N XLSHDWCSQQJPRO-UHFFFAOYSA-N 0.000 description 3
- IMFWDEILLRVLEB-UHFFFAOYSA-N 5-amino-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidine-8-carbonitrile Chemical compound NC1=NC(=C(C=2N1C=NN=2)C#N)C1=CC=CC=C1 IMFWDEILLRVLEB-UHFFFAOYSA-N 0.000 description 3
- NIKPZTDIIDLLNF-UHFFFAOYSA-N 5-bromo-4-hydrazinyl-6-phenylpyrimidin-2-amine Chemical compound BrC1=C(NN)N=C(N=C1C1=CC=CC=C1)N NIKPZTDIIDLLNF-UHFFFAOYSA-N 0.000 description 3
- WMNRWFCIVISFLU-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-methylsulfanylpyrimidin-4-amine Chemical compound CSc1nc(N)cc(n1)-c1ccc(F)cc1 WMNRWFCIVISFLU-UHFFFAOYSA-N 0.000 description 3
- SFTVRRODJYZMPO-UHFFFAOYSA-N 7-(2,4-difluorophenyl)-8-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC1=C(C=CC(=C1)F)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)C SFTVRRODJYZMPO-UHFFFAOYSA-N 0.000 description 3
- QZFLMONBGLUHMU-UHFFFAOYSA-N 7-(2,4-difluorophenyl)-8-(2-methoxy-6-methylpyridin-4-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC1=C(C=CC(=C1)F)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)OC QZFLMONBGLUHMU-UHFFFAOYSA-N 0.000 description 3
- JWJAUVIDJFRLQG-UHFFFAOYSA-N 7-(2,4-difluorophenyl)-8-(2-methylpyridin-4-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC1=C(C=CC(=C1)F)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC=C1)C JWJAUVIDJFRLQG-UHFFFAOYSA-N 0.000 description 3
- BKVZRNUDCQPKSU-UHFFFAOYSA-N 7-(2,4-difluorophenyl)-8-[2-(fluoromethyl)-6-methylpyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC1=C(C=CC(=C1)F)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)CF BKVZRNUDCQPKSU-UHFFFAOYSA-N 0.000 description 3
- HIMIMAKIQGAZMZ-UHFFFAOYSA-N 7-(2-chloro-4-fluorophenyl)-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=C(C=CC(=C1)F)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C(F)(F)F)C HIMIMAKIQGAZMZ-UHFFFAOYSA-N 0.000 description 3
- AOHJHNROZHNTEX-UHFFFAOYSA-N 7-(2-fluorophenyl)-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC1=C(C=CC=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C(F)(F)F)C AOHJHNROZHNTEX-UHFFFAOYSA-N 0.000 description 3
- FUSLSGFBMZMBDG-UHFFFAOYSA-N 7-(3-fluorophenyl)-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC=1C=C(C=CC=1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C(F)(F)F)C FUSLSGFBMZMBDG-UHFFFAOYSA-N 0.000 description 3
- CGLLDENMCTYBPV-UHFFFAOYSA-N 7-(4-chloro-2-fluorophenyl)-8-(2-chloro-6-methylpyridin-4-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=CC(=C(C=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)Cl)F CGLLDENMCTYBPV-UHFFFAOYSA-N 0.000 description 3
- KEZHSCYPPHEAQY-UHFFFAOYSA-N 7-(4-chloro-2-fluorophenyl)-8-[2-(difluoromethyl)-6-methylpyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=CC(=C(C=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)C(F)F)F KEZHSCYPPHEAQY-UHFFFAOYSA-N 0.000 description 3
- SVIJRVNCNAYTOL-UHFFFAOYSA-N 7-(4-chlorophenyl)-8-[2-(fluoromethyl)-6-methylpyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=CC=C(C=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)CF SVIJRVNCNAYTOL-UHFFFAOYSA-N 0.000 description 3
- QOAVITVAFHVVAU-UHFFFAOYSA-N 8-(2-chloro-6-methylpyridin-4-yl)-7-(4-methylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=C(C=C1)C)N)C=NN=2)C QOAVITVAFHVVAU-UHFFFAOYSA-N 0.000 description 3
- DXXWIWISMMUYCS-UHFFFAOYSA-N 8-(2-cyclopropyl-6-methylpyridin-4-yl)-7-(2,4-difluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C1(CC1)C1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=C(C=C(C=C1)F)F)N)C=NN=2)C DXXWIWISMMUYCS-UHFFFAOYSA-N 0.000 description 3
- IKIYTQPIBUCJTC-UHFFFAOYSA-N 8-[2-(difluoromethyl)-6-methylpyridin-4-yl]-7-(2,4-difluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC(C1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=C(C=C(C=C1)F)F)N)C=NN=2)C)F IKIYTQPIBUCJTC-UHFFFAOYSA-N 0.000 description 3
- ULIIOKKLPNSIKM-UHFFFAOYSA-N 8-[2-(difluoromethyl)-6-methylpyridin-4-yl]-7-(4-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC(C1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=C(C=C1)F)N)C=NN=2)C)F ULIIOKKLPNSIKM-UHFFFAOYSA-N 0.000 description 3
- UXINCTHDFPVPJY-UHFFFAOYSA-N 8-[2-(fluoromethyl)-6-methylpyridin-4-yl]-7-(2-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FCC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=C(C=CC=C1)F)N)C=NN=2)C UXINCTHDFPVPJY-UHFFFAOYSA-N 0.000 description 3
- CDIYTQSZQVJION-UHFFFAOYSA-N 8-[2-(fluoromethyl)-6-methylpyridin-4-yl]-7-(4-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FCC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=C(C=C1)F)N)C=NN=2)C CDIYTQSZQVJION-UHFFFAOYSA-N 0.000 description 3
- NVMVMAYZLFVCPW-UHFFFAOYSA-N 8-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-7-(2,4-difluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=C(C=C(C=C1)F)F)N)C=NN=2)C(F)(F)F NVMVMAYZLFVCPW-UHFFFAOYSA-N 0.000 description 3
- FAJYJZNSPSHKOR-UHFFFAOYSA-N 8-[2-methyl-6-[(4-methylpiperazin-1-yl)methyl]pyridin-4-yl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)CN1CCN(CC1)C FAJYJZNSPSHKOR-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- NEEQSFAQGTVCRX-UHFFFAOYSA-N 8-bromo-5-methylsulfonyl-7-phenylimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)S(=O)(=O)C)C=CN=2 NEEQSFAQGTVCRX-UHFFFAOYSA-N 0.000 description 3
- XKIFTTGLWMFTSJ-UHFFFAOYSA-N 8-bromo-7-(4-methylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=C(C=C1)C)N)C=NN=2 XKIFTTGLWMFTSJ-UHFFFAOYSA-N 0.000 description 3
- OHJOAQJXSADOJM-UHFFFAOYSA-N 8-bromo-7-(5-methylfuran-2-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C=1OC(=CC=1)C)N)C=NN=2 OHJOAQJXSADOJM-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- RFHZASSDNNOJND-UHFFFAOYSA-M C(C)(=O)[O-].C[Si](C)(C)N([Si](C)(C)C)[K].C(C)(C)N(C(C)C)[Li].[Li+] Chemical compound C(C)(=O)[O-].C[Si](C)(C)N([Si](C)(C)C)[K].C(C)(C)N(C(C)C)[Li].[Li+] RFHZASSDNNOJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- SBWJERDWKYNUFP-UHFFFAOYSA-N dibenzylphosphane Chemical compound C=1C=CC=CC=1CPCC1=CC=CC=C1 SBWJERDWKYNUFP-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- QQLRSCZSKQTFGY-UHFFFAOYSA-N (2,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1F QQLRSCZSKQTFGY-UHFFFAOYSA-N 0.000 description 2
- SLTBMTIRYMGWLX-XMMPIXPASA-N (2r)-2-[(4-chloroanilino)carbamoylamino]-3-(1h-indol-3-yl)-n-(2-phenylethyl)propanamide Chemical compound C1=CC(Cl)=CC=C1NNC(=O)N[C@@H](C(=O)NCCC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 SLTBMTIRYMGWLX-XMMPIXPASA-N 0.000 description 2
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 description 2
- YBNDRTRLXPEWKQ-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)boronic acid Chemical group OB(O)C1=CC=C(Cl)C=C1F YBNDRTRLXPEWKQ-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- YCGQPIRMLGEWMW-UHFFFAOYSA-N 1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN(C)C)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 YCGQPIRMLGEWMW-UHFFFAOYSA-N 0.000 description 2
- YKYWUHHZZRBGMG-JWTNVVGKSA-N 1-methyl-2-[[(1r,5s)-6-[[5-(trifluoromethyl)pyridin-2-yl]methoxymethyl]-3-azabicyclo[3.1.0]hexan-3-yl]methyl]benzimidazole Chemical compound C1([C@@H]2CN(C[C@@H]21)CC=1N(C2=CC=CC=C2N=1)C)COCC1=CC=C(C(F)(F)F)C=N1 YKYWUHHZZRBGMG-JWTNVVGKSA-N 0.000 description 2
- FJMQJSUOOGOWBD-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one Chemical compound O=C1N(CC(F)(F)C)CCOC=2C1=NN(C=1C(=CC=CC=1)Cl)C=2C1=CC=C(Cl)C=C1 FJMQJSUOOGOWBD-UHFFFAOYSA-N 0.000 description 2
- PFQYGHGKTNHYRQ-UHFFFAOYSA-N 2-(chloromethyl)-6-methylpyridine Chemical compound CC1=CC=CC(CCl)=N1 PFQYGHGKTNHYRQ-UHFFFAOYSA-N 0.000 description 2
- IJRZUKDWVCBYEL-UHFFFAOYSA-N 2-[(2-methylsulfanyl-6-phenylpyrimidin-4-yl)amino]propan-1-ol Chemical compound CSC1=NC(=CC(=N1)NC(CO)C)C1=CC=CC=C1 IJRZUKDWVCBYEL-UHFFFAOYSA-N 0.000 description 2
- CJLZUKCACMUYFP-GOSISDBHSA-N 2-[(5R)-4-[2-[3-(3-methylbutanoyloxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound CC(C)CC(=O)OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 CJLZUKCACMUYFP-GOSISDBHSA-N 0.000 description 2
- RYWCQJDEHXJHRI-XJMXIVSISA-N 2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC(C(=C1)C=2C=C(CC(O)=O)C=CC=2)=CC=C1CCCCCCC(C=C1C=2C=C(CC(O)=O)C=CC=2)=CC=C1O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RYWCQJDEHXJHRI-XJMXIVSISA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- JPZOAVGMSDSWSW-UHFFFAOYSA-N 4,6-dichloropyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(Cl)=N1 JPZOAVGMSDSWSW-UHFFFAOYSA-N 0.000 description 2
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 2
- ZEESGEQPRKDJCQ-UHFFFAOYSA-N 4-chloro-2-methylsulfanyl-6-phenylpyrimidine Chemical compound CSC1=NC(Cl)=CC(C=2C=CC=CC=2)=N1 ZEESGEQPRKDJCQ-UHFFFAOYSA-N 0.000 description 2
- XNMAKOHFKQAKPX-UHFFFAOYSA-N 4-chloro-5-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-6-phenylpyrimidin-2-amine Chemical compound ClC1=NC(=NC(=C1C1=CC(=NC(=C1)C(F)(F)F)C)C1=CC=CC=C1)N XNMAKOHFKQAKPX-UHFFFAOYSA-N 0.000 description 2
- CFFCGIWEXNJMBL-UHFFFAOYSA-N 4-chloro-5-iodo-6-phenylpyrimidin-2-amine Chemical compound NC1=NC(Cl)=C(I)C(C=2C=CC=CC=2)=N1 CFFCGIWEXNJMBL-UHFFFAOYSA-N 0.000 description 2
- QJGQFLJJYMEECH-UHFFFAOYSA-N 4-chloro-6-(2,4-difluorophenyl)pyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(C=2C(=CC(F)=CC=2)F)=N1 QJGQFLJJYMEECH-UHFFFAOYSA-N 0.000 description 2
- BQKZVMOSYDOEOR-UHFFFAOYSA-N 4-chloro-6-(2-fluorophenyl)pyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(C=2C(=CC=CC=2)F)=N1 BQKZVMOSYDOEOR-UHFFFAOYSA-N 0.000 description 2
- UZJYHEPDMNCKQG-UHFFFAOYSA-N 4-chloro-6-(4-chlorophenyl)pyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(C=2C=CC(Cl)=CC=2)=N1 UZJYHEPDMNCKQG-UHFFFAOYSA-N 0.000 description 2
- ASTAWZNNWSUZRL-UHFFFAOYSA-N 4-chloro-6-(4-fluorophenyl)pyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(C=2C=CC(F)=CC=2)=N1 ASTAWZNNWSUZRL-UHFFFAOYSA-N 0.000 description 2
- FIPBRZXDWSODDX-UHFFFAOYSA-N 4-chloro-6-phenylpyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(C=2C=CC=CC=2)=N1 FIPBRZXDWSODDX-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- QGGIRLHCJLRWRI-UHFFFAOYSA-N 5-bromo-2-methylsulfanyl-6-phenylpyrimidin-4-amine Chemical compound BrC=1C(=NC(=NC=1C1=CC=CC=C1)SC)N QGGIRLHCJLRWRI-UHFFFAOYSA-N 0.000 description 2
- LAUORAFVFXRKDL-UHFFFAOYSA-N 5-bromo-4,6-dichloropyrimidin-2-amine Chemical compound NC1=NC(Cl)=C(Br)C(Cl)=N1 LAUORAFVFXRKDL-UHFFFAOYSA-N 0.000 description 2
- YTGMLONMSZMTGX-UHFFFAOYSA-N 5-bromo-4-(4-chlorophenyl)-6-hydrazinylpyrimidin-2-amine Chemical compound N(C1=C(Br)C(C2=CC=C(Cl)C=C2)=NC(=N1)N)N YTGMLONMSZMTGX-UHFFFAOYSA-N 0.000 description 2
- XPMNBJPRLZTPJE-UHFFFAOYSA-N 5-bromo-4-(4-fluorophenyl)-6-hydrazinylpyrimidin-2-amine Chemical compound N(C1=C(Br)C(C2=CC=C(F)C=C2)=NC(=N1)N)N XPMNBJPRLZTPJE-UHFFFAOYSA-N 0.000 description 2
- LHLADCYPSCRZOO-UHFFFAOYSA-N 5-bromo-4-chloro-6-(4-chlorophenyl)pyrimidin-2-amine Chemical compound BrC=1C(=NC(=NC=1C1=CC=C(C=C1)Cl)N)Cl LHLADCYPSCRZOO-UHFFFAOYSA-N 0.000 description 2
- VXNDLTFBXXUTFS-UHFFFAOYSA-N 5-bromo-4-chloro-6-(5-methylfuran-2-yl)pyrimidin-2-amine Chemical compound BrC=1C(=NC(=NC=1C=1OC(=CC=1)C)N)Cl VXNDLTFBXXUTFS-UHFFFAOYSA-N 0.000 description 2
- YLMFTTBYMVQLMH-UHFFFAOYSA-N 5-bromo-7-(trifluoromethyl)-1h-indazole Chemical compound FC(F)(F)C1=CC(Br)=CC2=C1NN=C2 YLMFTTBYMVQLMH-UHFFFAOYSA-N 0.000 description 2
- ISWLAMCDXBYLHD-UHFFFAOYSA-N 5-bromo-7-fluoro-1h-indazole Chemical compound FC1=CC(Br)=CC2=C1NN=C2 ISWLAMCDXBYLHD-UHFFFAOYSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- FCBOUJYKAGWYQM-DEOSSOPVSA-N 6-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]-n-(2-phenoxyethyl)-2-(3,4,5-trimethoxyphenyl)pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(N[C@H](CO)CC=3C=CC=CC=3)N=2)C(=O)NCCOC=2C=CC=CC=2)=C1 FCBOUJYKAGWYQM-DEOSSOPVSA-N 0.000 description 2
- DDCOYWOYIUEOHQ-UHFFFAOYSA-N 6-bromo-8-fluoroquinoline Chemical compound C1=CN=C2C(F)=CC(Br)=CC2=C1 DDCOYWOYIUEOHQ-UHFFFAOYSA-N 0.000 description 2
- RYYKJLRAFMKRSC-UHFFFAOYSA-N 6-bromo-8-methylquinoline Chemical compound C1=CN=C2C(C)=CC(Br)=CC2=C1 RYYKJLRAFMKRSC-UHFFFAOYSA-N 0.000 description 2
- ISUXMAHVLFRZQU-UHFFFAOYSA-N 6-chloro-2-methylsulfanylpyrimidin-4-amine Chemical compound CSC1=NC(N)=CC(Cl)=N1 ISUXMAHVLFRZQU-UHFFFAOYSA-N 0.000 description 2
- LAAQYGIJDAHUTM-UHFFFAOYSA-N 7-(5-methylfuran-2-yl)-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C=1OC(=CC=1)C)N)C=NN=2)C(F)(F)F LAAQYGIJDAHUTM-UHFFFAOYSA-N 0.000 description 2
- SOTWHXZHXPNLSF-UHFFFAOYSA-N 7-phenyl-8-[7-(trifluoromethyl)-1H-indazol-5-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C1(=CC=CC=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C=1C=C2C=NNC2=C(C=1)C(F)(F)F SOTWHXZHXPNLSF-UHFFFAOYSA-N 0.000 description 2
- BLDKNBILZZETDD-UHFFFAOYSA-N 8-(2,6-dimethylpyridin-4-yl)-2-methyl-7-phenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=C(N=2)C)C BLDKNBILZZETDD-UHFFFAOYSA-N 0.000 description 2
- WBEQFIXFBVCQJG-UHFFFAOYSA-N 8-(2,6-dimethylpyridin-4-yl)-7-(2-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=C(C=CC=C1)F)N)C=NN=2)C WBEQFIXFBVCQJG-UHFFFAOYSA-N 0.000 description 2
- XFHWLSWRPMZDRV-UHFFFAOYSA-N 8-(2-chloro-6-methylpyridin-4-yl)-7-(4-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=C(C=C1)F)N)C=NN=2)C XFHWLSWRPMZDRV-UHFFFAOYSA-N 0.000 description 2
- JXSLUWIGQKHRGK-UHFFFAOYSA-N 8-(7-fluoro-1H-indazol-5-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC=1C=C(C=C2C=NNC=12)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2 JXSLUWIGQKHRGK-UHFFFAOYSA-N 0.000 description 2
- JPFQHWSQTRSHLZ-UHFFFAOYSA-N 8-(8-fluoroquinolin-6-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound FC=1C=C(C=C2C=CC=NC=12)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2 JPFQHWSQTRSHLZ-UHFFFAOYSA-N 0.000 description 2
- KDGKRRSVUPFUSN-UHFFFAOYSA-N 8-(8-methylquinolin-6-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC=1C=C(C=C2C=CC=NC=12)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2 KDGKRRSVUPFUSN-UHFFFAOYSA-N 0.000 description 2
- ILODIRYIWQIJFD-UHFFFAOYSA-N 8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)C(F)(F)F ILODIRYIWQIJFD-UHFFFAOYSA-N 0.000 description 2
- ULWSUVDQFUPUDB-UHFFFAOYSA-N 8-bromo-5-methylsulfanyl-7-phenylimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)SC)C=CN=2 ULWSUVDQFUPUDB-UHFFFAOYSA-N 0.000 description 2
- RVVLSPBFURXWLD-UHFFFAOYSA-N 8-bromo-7-(2,4-difluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=C(C=C(C=C1)F)F)N)C=NN=2 RVVLSPBFURXWLD-UHFFFAOYSA-N 0.000 description 2
- YIOMPKUUDATRAV-UHFFFAOYSA-N 8-bromo-7-(2-chloro-4-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=C(C=C(C=C1)F)Cl)N)C=NN=2 YIOMPKUUDATRAV-UHFFFAOYSA-N 0.000 description 2
- JFYUPCMRNTZOTC-UHFFFAOYSA-N 8-bromo-7-(2-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=C(C=CC=C1)F)N)C=NN=2 JFYUPCMRNTZOTC-UHFFFAOYSA-N 0.000 description 2
- UGQNQZLNBGMRBM-UHFFFAOYSA-N 8-bromo-7-(4-chloro-2-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=C(C=C(C=C1)Cl)F)N)C=NN=2 UGQNQZLNBGMRBM-UHFFFAOYSA-N 0.000 description 2
- NTDGCRMVYONOFW-UHFFFAOYSA-N 8-bromo-7-(4-chlorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=C(C=C1)Cl)N)C=NN=2 NTDGCRMVYONOFW-UHFFFAOYSA-N 0.000 description 2
- RDQCGYOKRVKLBX-UHFFFAOYSA-N 8-bromo-7-(4-fluorophenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=C(C=C1)F)N)C=CN=2 RDQCGYOKRVKLBX-UHFFFAOYSA-N 0.000 description 2
- OMJFXBRMEQVDJD-UHFFFAOYSA-N 8-bromo-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2 OMJFXBRMEQVDJD-UHFFFAOYSA-N 0.000 description 2
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 2
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000662429 Fenerbahce Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- UJQAHAANAPEYLR-UHFFFAOYSA-N [2-chloro-6-[2,4,6-tri(propan-2-yl)phenyl]phenyl]-dicyclohexylphosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(Cl)=C1P(C1CCCCC1)C1CCCCC1 UJQAHAANAPEYLR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940127206 compound 14d Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- DVWOYOSIEJRHKW-UIRZNSHLSA-M sodium (2S)-2-[[(2S)-2-[[(4,4-difluorocyclohexyl)-phenylmethoxy]carbonylamino]-4-methylpentanoyl]amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate Chemical compound FC1(CCC(CC1)C(OC(=O)N[C@H](C(=O)N[C@H](C(S(=O)(=O)[O-])O)C[C@H]1C(NCC1)=O)CC(C)C)C1=CC=CC=C1)F.[Na+] DVWOYOSIEJRHKW-UIRZNSHLSA-M 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- VYXHVRARDIDEHS-QGTKBVGQSA-N (1z,5z)-cycloocta-1,5-diene Chemical compound C\1C\C=C/CC\C=C/1 VYXHVRARDIDEHS-QGTKBVGQSA-N 0.000 description 1
- MNKCGUKVRJZKEQ-MIXQCLKLSA-N (1z,5z)-cycloocta-1,5-diene;iridium;methanol Chemical compound [Ir].[Ir].OC.OC.C\1C\C=C/CC\C=C/1.C\1C\C=C/CC\C=C/1 MNKCGUKVRJZKEQ-MIXQCLKLSA-N 0.000 description 1
- XOFNMNLYGPKKOV-UHFFFAOYSA-N (2-chloro-4-fluorophenyl)boronic acid Chemical group OB(O)C1=CC=C(F)C=C1Cl XOFNMNLYGPKKOV-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- DJXZIOJMSWYBCY-SDBHATRESA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-pentyloxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(CCCCC)O[C@H](CO)[C@@H](O)[C@H]1O DJXZIOJMSWYBCY-SDBHATRESA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical group CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- 239000001211 (E)-4-phenylbut-3-en-2-one Substances 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- 0 **C(*(C=*)C1=*)=C(*)C(c2ccccc2)=C1C1=CC(C*CCO)=*CC(N)=C1 Chemical compound **C(*(C=*)C1=*)=C(*)C(c2ccccc2)=C1C1=CC(C*CCO)=*CC(N)=C1 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical group CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- MXPCZHSTOIKVST-UHFFFAOYSA-N 1-[3-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=CC(N)=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCO)=C1 MXPCZHSTOIKVST-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical group COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZGGLVBJUELTPIK-UHFFFAOYSA-N 4-[(6-chloropyridin-2-yl)methyl]morpholine Chemical compound ClC1=CC=CC(CN2CCOCC2)=N1 ZGGLVBJUELTPIK-UHFFFAOYSA-N 0.000 description 1
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- UCDAJJNCBUNIGL-UHFFFAOYSA-N 7-(4-chloro-2-fluorophenyl)-8-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=CC(=C(C=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C(F)(F)F)C)F UCDAJJNCBUNIGL-UHFFFAOYSA-N 0.000 description 1
- SFXZMODENBPXHL-UHFFFAOYSA-N 7-(4-chlorophenyl)-8-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=CC=C(C=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC(=NC(=C1)C)C SFXZMODENBPXHL-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- OCTJELYAKFWRAG-UHFFFAOYSA-N 7-phenyl-8-pyridin-4-yl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C1(=CC=CC=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C1=CC=NC=C1 OCTJELYAKFWRAG-UHFFFAOYSA-N 0.000 description 1
- WKPXEMPFLXSVPV-UHFFFAOYSA-N 7-phenyl-8-quinolin-6-yl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C1(=CC=CC=C1)C1=C(C=2N(C(=N1)N)C=NN=2)C=1C=C2C=CC=NC2=CC=1 WKPXEMPFLXSVPV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RAJLWMDVQMQVLF-UHFFFAOYSA-N 8-(1H-indazol-5-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C=1N2C(=NN=1)C(C1=CC=3C=NNC=3C=C1)=C(C1=CC=CC=C1)N=C2N RAJLWMDVQMQVLF-UHFFFAOYSA-N 0.000 description 1
- CUZVDGBABICSNN-UHFFFAOYSA-N 8-(2,6-dimethylpyridin-4-yl)-7-(4-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=C(C=C1)F)N)C=NN=2)C CUZVDGBABICSNN-UHFFFAOYSA-N 0.000 description 1
- QSRRHQOMEODMHF-UHFFFAOYSA-N 8-(2,6-dimethylpyridin-4-yl)-7-(4-fluorophenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=C(C=C1)F)N)C=CN=2)C QSRRHQOMEODMHF-UHFFFAOYSA-N 0.000 description 1
- UWKRVZZTWLFMIF-UHFFFAOYSA-N 8-(2,6-dimethylpyridin-4-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)C UWKRVZZTWLFMIF-UHFFFAOYSA-N 0.000 description 1
- QPCDDBXXNNPLMF-UHFFFAOYSA-N 8-(2,6-dimethylpyridin-4-yl)-7-phenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound CC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=CN=2)C QPCDDBXXNNPLMF-UHFFFAOYSA-N 0.000 description 1
- GIAZMXDTFJDQBK-UHFFFAOYSA-N 8-(2-chloro-6-methylpyridin-4-yl)-7-(2-fluorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=C(C=CC=C1)F)N)C=NN=2)C GIAZMXDTFJDQBK-UHFFFAOYSA-N 0.000 description 1
- KDIGMROYUOEKTJ-UHFFFAOYSA-N 8-(2-chloro-6-methylpyridin-4-yl)-7-(4-chlorophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=C(C=C1)Cl)N)C=NN=2)C KDIGMROYUOEKTJ-UHFFFAOYSA-N 0.000 description 1
- CXIZRWNZDYIGEA-UHFFFAOYSA-N 8-(2-chloro-6-methylpyridin-4-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)C CXIZRWNZDYIGEA-UHFFFAOYSA-N 0.000 description 1
- YCBFXJBOLVFSSF-UHFFFAOYSA-N 8-(2-chloro-6-methylpyridin-4-yl)-7-phenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=CN=2)C YCBFXJBOLVFSSF-UHFFFAOYSA-N 0.000 description 1
- OQRHRHLGSRKOOX-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2 OQRHRHLGSRKOOX-UHFFFAOYSA-N 0.000 description 1
- HWPHKAOQDAQSRN-UHFFFAOYSA-N 8-(2-cyclopropyl-6-methylpyridin-4-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C1(CC1)C1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)C HWPHKAOQDAQSRN-UHFFFAOYSA-N 0.000 description 1
- YLNLOEKWGXAJSQ-UHFFFAOYSA-N 8-(2-ethyl-6-methylpyridin-4-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound C(C)C1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)C YLNLOEKWGXAJSQ-UHFFFAOYSA-N 0.000 description 1
- FSJWFYZEXUEROR-UHFFFAOYSA-N 8-(2-methoxy-6-methylpyridin-4-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound COC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)C FSJWFYZEXUEROR-UHFFFAOYSA-N 0.000 description 1
- KJLKCROBAWPDJK-UHFFFAOYSA-N 8-(2-methylpyridin-4-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound CC1=NC=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2 KJLKCROBAWPDJK-UHFFFAOYSA-N 0.000 description 1
- JYSLFQTWNRYWJT-UHFFFAOYSA-N 8-(3,5-dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine Chemical compound N=1C2=C(N)N=CN=C2N(CCCNC(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 JYSLFQTWNRYWJT-UHFFFAOYSA-N 0.000 description 1
- WKLXOWXTEYEASY-UHFFFAOYSA-N 8-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine Chemical compound ClC1=NC(=CC(=C1)C=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=NN=2)C(F)(F)F WKLXOWXTEYEASY-UHFFFAOYSA-N 0.000 description 1
- MMQGVIOQSADAAT-UHFFFAOYSA-N 8-bromo-2-methyl-7-phenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound BrC=1C=2N(C(=NC=1C1=CC=CC=C1)N)C=C(N=2)C MMQGVIOQSADAAT-UHFFFAOYSA-N 0.000 description 1
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 1
- 108010060263 Adenosine A1 Receptor Proteins 0.000 description 1
- 102000030814 Adenosine A1 receptor Human genes 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
- 102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OAWMRBZYZCQZMV-UHFFFAOYSA-M C(C)(=O)[O-].N[K].[Li+] Chemical compound C(C)(=O)[O-].N[K].[Li+] OAWMRBZYZCQZMV-UHFFFAOYSA-M 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- VUWBMXNMKRWSEI-UHFFFAOYSA-N C1(CCCCC1)P(C1=C(C=CC=C1)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C)C1CCCCC1.[Cl] Chemical group C1(CCCCC1)P(C1=C(C=CC=C1)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C)C1CCCCC1.[Cl] VUWBMXNMKRWSEI-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- PGTBFSOXUWNUBJ-UHFFFAOYSA-N [P]Cc1ccccc1 Chemical compound [P]Cc1ccccc1 PGTBFSOXUWNUBJ-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 229930008407 benzylideneacetone Natural products 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126212 compound 17a Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical group C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YLBGJNSKBVFLEZ-UHFFFAOYSA-N dimethylthallium Chemical compound C[Tl]C YLBGJNSKBVFLEZ-UHFFFAOYSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SORXVYYPMXPIFD-UHFFFAOYSA-N iron palladium Chemical compound [Fe].[Pd] SORXVYYPMXPIFD-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- WBGPNPZUWVTYAA-UHFFFAOYSA-N methane;dihydrochloride Chemical compound C.Cl.Cl WBGPNPZUWVTYAA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-O methyloxidanium Chemical compound [OH2+]C OKKJLVBELUTLKV-UHFFFAOYSA-O 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- RAIWYFYCHWDSOE-UHFFFAOYSA-N n,n-di(propan-2-yl)butan-2-amine Chemical compound CCC(C)N(C(C)C)C(C)C RAIWYFYCHWDSOE-UHFFFAOYSA-N 0.000 description 1
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- SKEAGJWUKCNICJ-LSDHHAIUSA-N n-[(4-fluoro-3-methoxyphenyl)methyl]-6-[2-[[(2s,5r)-5-(hydroxymethyl)-1,4-dioxan-2-yl]methyl]tetrazol-5-yl]-2-methylpyrimidine-4-carboxamide Chemical group C1=C(F)C(OC)=CC(CNC(=O)C=2N=C(C)N=C(C=2)C2=NN(C[C@@H]3OC[C@@H](CO)OC3)N=N2)=C1 SKEAGJWUKCNICJ-LSDHHAIUSA-N 0.000 description 1
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 1
- CJPMSUUANYLPET-UHFFFAOYSA-N n-[3-[[5-cyclopropyl-2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCCNC(C(=CN=1)C2CC2)=NC=1NC(C=C1)=CC=C1N1CCOCC1 CJPMSUUANYLPET-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000026517 ureter neoplasm Diseases 0.000 description 1
- 201000011476 ureteral benign neoplasm Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本發明涉及雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用。具體而言,本發明涉及一種通式(I)所示的雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及含有該衍生物的醫藥組成物以及其作為治療劑,特別是作為A2a受體拮抗劑的用途和在製備用於治療藉由對A2a受體的抑制而改善的病況或病症的藥物中的用途,其中通式(I)的各取代基與說明書中的定義相同。
Description
本發明屬於醫藥領域,涉及一種通式(I)所示的雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及含有該衍生物的醫藥組成物以及其作為治療劑,特別是作為A2a受體拮抗劑的用途和在製備用於治療藉由對A2a受體的抑制而改善的病況或病症的藥物中的用途。
腺苷是天然存在的嘌呤核苷,是許多生理功能的內源性調節劑。在心血管系統、中樞神經、呼吸系統、腎臟、脂肪和血小板的功能調節中發揮重要作用。
腺苷的作用由G蛋白偶聯受體家族介導,目前已知至少有四種亞型的腺苷受體,分類為A1、A2a、A2b和A3。其中A1和A3受體抑制酶腺苷酸環化酶的活性,而A2a和A2b受體刺激該酶的活性,由此調節細胞中環AMP水準,藉由這些受體,腺苷調節廣泛的生理功能。
A2a受體(A2aR)在機體分佈較為廣泛,在中樞神經系統 主要表現於紋狀體,在外周、心、肝、肺、腎等組織也均有表現。數個臨床前研究表明,腺苷A2a受體拮抗劑對於治療神經變性疾病,主要是帕金森病、亨廷頓病或阿茲海默症具有驚人療效(Trends in Neurosci.2006,29(11),647-654;Expert Opinion on Therapeutic Patents,2007,17,979-991等)。而且也可以用於治療其他中樞神經系統(CNS)相關的疾病例如抑鬱、過動症候群、睡眠障礙和焦慮症(Clin.Neuropharmacol.2010,33,55-60;J.Neurosci.2010,30(48),16284-16292;Parkinsonisn Relat.Disord.2010,16(6),423-426;及其中的參考獻:Mov.Disorders,2010,25(2),S305)。此外,腺苷A2a受體拮抗劑還具有作為神經保護劑的治療潛力(參見Jenner P.J Neuro 1.2000;24 7Suppl2:1143-50)。
近來研究表明,在缺血低氧、炎症、創傷、移植等諸多病理過程中,腺苷A2a受體的啟動可以發揮重要的免疫調節作用,這可能與A2a受體在T細胞、B細胞、單核巨噬細胞、嗜中性球等多種免疫細胞上表現水準較高有關。此外,A2a受體的活化可以促使機體產生免疫耐受,密切參與了腫瘤細胞“免疫逃逸”或“免疫抑制”的形成,為腫瘤的發生發展創造了有利條件。Lokshin及其同事(Cancer Res.2006 Augl;66(15):7758-65)證實自然殺傷細胞上的A2a受體活化可以藉由升高cAMP,啟動PKA抑制自然殺傷細胞對腫瘤細胞的殺傷。還有研究表明,啟動A2a受體的活化可以促進黑色素瘤A375細胞、成纖維瘤NIH3T3細胞及嗜 鉻細胞瘤PC12細胞等腫瘤細胞的增殖,其可能與T細胞上A2a受體的活化可以抑制T細胞活化、增殖、與腫瘤細胞的黏附及對腫瘤細胞產生細胞毒性作用相關;而A2a受體基因敲除的小鼠則可以加強CD8+T細胞抗腫瘤的免疫作用,顯著抑制腫瘤的增殖。因此,A2a受體拮抗劑也可用於腫瘤的治療。
儘管對多種腺苷受體亞型具有顯著生物學活性的化合物可具有治療作用,但它們可導致不想要的副作用。例如腺苷A1受體在組織缺血/缺氧時,在中樞、循環、消化系統和骨骼肌中,細胞在處於缺氧和低氧的壓力環境時,胞外聚集的腺苷藉由啟動胞膜上的A1受體啟動相應的保護機制,從而增加細胞對缺氧低氧的耐受。位於免疫細胞上的A1受體在低氧環境中能促進細胞免疫反應。另外,A1受體還能降低游離脂肪酸和三酸甘油酯,參與調節血糖。因此,A1受體的持續阻斷可能會引起有機體組織中各種不良反應的發生(Chinese Pharmacological Bulletin,2008,24(5),573-576)。如有文獻報導,在動物模型上,阻斷A1受體將會產生焦慮、覺醒等不良反應(Basic & Clinical Pharmacology & Toxicology,2011,109(3),203-7)。腺苷受體A3(如Gessi S等人,Pharmacol.Ther.117(1),2008,123-140所述)在心肌缺血期間釋放的腺苷在心臟中發揮強力的保護作用,A3受體的持續阻斷可能增加由任何預先存在的或正在發展的缺血性心臟病引起的併發症的可能性,所述缺血性心臟病諸如心絞痛或心衰竭。
目前,雖然已有許多化合物經開發為A2a受體的拮抗劑用於治療很多疾病,如WO2007116106、WO2009080197、WO2011159302、WO2011095625、WO2014101373、WO2015031221中所述。但仍有低溶解性、光敏性、低活性、低選擇性和生物利用率較低等問題存在。
本發明提供一種新型雜芳基并[4,3-c]嘧啶-5-胺類結構的腺苷A2a受體拮抗劑,并發現具有此類結構的化合物具有強抑制活性和高選擇性,并且此類結構的化合物在腦中的游離藥物濃度低,透過血腦屏障能力弱,對藥物進腦後可能產生的副作用低。
本發明的目的在於提供一種通式(I)所示的化合物:
或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中:G為N或CR4;環A選自環烷基、芳基和雜芳基; R1相同或不同,各自獨立地選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基和雜芳基;R2選自烷氧基、羥基、氰基、胺基、硝基、環烷基、雜環基、芳基和雜芳基;其中所述的烷氧基、環烷基、雜環基、芳基和雜芳基各自獨立地視需要經選自鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氧代基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基、C(O)OR5和Rb中的一個或多個取代基所取代;R3選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基和雜芳基;R4選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基和雜芳基;R5選自氫原子、烷基、胺基、鹵烷基、環烷基、雜環基、芳基和雜芳基;Rb為雜環基烷基,其中所述的雜環基烷基中的雜環基視需要經選自烷氧基、羥基、羥烷基、氰基、胺基、硝基、環烷基、環烷基氧基、雜環基、芳基、雜芳基和C(O)OR5中的一個或多個取代基所取代;且n為1、2、3或4。
在本發明一個較佳的實施方案中,所述的通式(I)所示的化合物,其中所述的R2選自氰基、環烷基、雜環基、芳 基和雜芳基;其中所述的環烷基、雜環基、芳基和雜芳基各自獨立地視需要經選自鹵素、烷基、鹵烷基、烷氧基、氧代基、環烷基、雜環基和Rb中的一個或多個取代基所取代;Rb為雜環基烷基,其中所述的雜環基烷基中的雜環基視需要經一個或多個烷基所取代。
在本發明一個較佳的實施方案中,所述的通式(I)所示的化合物為通式(II)所示的化合物:
或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中:環B選自環烷基、雜環基、芳基和雜芳基;R6相同或不同,各自獨立地選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氧代基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基、C(O)OR5和Rb;s為0、1、2、3或4;且環A、G、R1、R3、R5、Rb和n如通式(I)中所定義。
在本發明一個較佳的實施方案中,所述的通式(I)所示的化合物為通式(III)所示的化合物:
或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中:R6相同或不同,各自獨立地選自鹵素、烷基、鹵烷基、烷氧基、氧代基、環烷基、雜環基和Rb;Rb為雜環基烷基,其中所述的雜環基烷基中的雜環基視需要經一個或多個烷基所取代;環A、環B、R1、R3、n和s如通式(II)中所定義。
在本發明一個較佳的實施方案中,所述的通式(II)所示的化合物,其中所述環B選自苯基、5至6員雜環基或5至10員雜芳基;較佳係苯基、吡啶基、吡唑基、吡啶-2-酮基、咪唑基、吡咯基、呋喃基、噻吩基、哌啶基、1,2,3,6-四氫吡啶基、異喹啉基、喹啉基、喹 啉基、吲哚基、吲唑基、苯并呋喃基或苯并噻吩基。
在本發明一個較佳的實施方案中,所述的通式(I)所示的化合物為通式(III’)所示的化合物:
或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中:R6相同或不同,各自獨立地選自氫原子、鹵素、烷基、鹵烷基、烷氧基、氧代基、環烷基、雜環基和Rb;Rb為雜環基烷基,其中所述的雜環基烷基中的雜環基視需要經一個或多個烷基所取代;s為0、1、2、3或4;環A、R1、R3和n如通式(I)中所定義。
在本發明一個較佳的實施方案中,所述的通式(I)所示的化合物,其中所述的環A為芳基或雜芳基,較佳為苯基或呋喃基。
在本發明一個較佳的實施方案中,所述的通式(I)所示的化合物,其中所述的R1選自氫原子、鹵素或烷基。
在本發明一個較佳的實施方案中,所述的通式(I)所示的化合物,其中所述的R3選自氫原子、鹵素或烷基。
本發明的典型化合物包括,但不限於:
或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽。
本發明的另一方面涉及一種通式(IV)所示的化合物:
或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中:X為鹵素;環A、G、R1、R3和n如通式(I)中所定義。
本發明的典型化合物包括,但不限於:
本發明的另一方面涉及一種製備通式(II)所示的化合物的方法,該方法包括:
通式(IV)的化合物和通式(V)的化合物反應,得到通式(II)的化合物,其中:X為鹵素;W為或環A、環B、G、R1、R3、R6、n和s如通式(I)中所定義。
本發明的另一方面涉及一種醫藥組成物,所述醫藥組成物含有治療有效量的本發明通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,以及一種或多種醫藥上可接受的載體、稀釋劑或賦形劑。
本發明進一步涉及通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物在製備用於抑制A2a受體的藥物中的用途。
本發明進一步涉及通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物在製備用於治療藉由對A2a受體抑制而改善的病況或病症的藥物中的用途。
在本發明中,藉由對A2a受體抑制而改善的病況或病症選自腫瘤、抑鬱症、認知功能病症、神經退行性病症(帕金森氏病、亨廷頓氏病、阿茲海默症或肌萎縮性側索硬化等)、注意力相關病症、錐體外症候群、異常運動障礙、肝硬化、肝纖維化、脂肪肝、皮膚纖維化、睡眠障礙、中風、腦損傷、神經炎症和成癮行為;較佳為腫瘤。
本發明進一步涉及通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物在製備治療腫瘤、抑鬱症、認知功能病症、神經退行性病症(帕金森氏病、亨廷頓氏病、阿茲海默症或肌萎縮性側索硬化等)、注意力相關病症、錐體外症候群、異常運動障礙、肝硬化、肝纖維化、脂肪肝、皮膚纖維化、睡眠障礙、中風、腦損傷、神經炎症和成癮行為,較佳腫瘤的藥物中的用途。
本發明進一步涉及通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物在製備治療腫瘤的藥物中的用途。
本發明還涉及一種抑制A2a受體的方法,其包括給予所需患者治療有效量的通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物。
本發明還涉及一種治療藉由對A2a受體抑制而改善的病況或病症的方法,其包括給予所需患者治療有效量的通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物。
本發明涉及一種治療腫瘤、抑鬱症、認知功能病症、神經退行性病症(帕金森氏病、亨廷頓氏病、阿茲海默症或肌萎縮性側索硬化等)、注意力相關病症、錐體外症候群、異常運動障礙、肝硬化、肝纖維化、脂肪肝、皮膚纖維化、睡眠障礙、中風、腦損傷、神經炎症和成癮行為,較佳腫瘤的方法,其包括給予所需患者治療有效量的通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物。
本發明進一步涉及一種通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式、或其醫藥上可接受之鹽或包含其醫藥組成物,其用作藥物。
本發明還涉及通式(I)所示的化合物或其互變異構 體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物,其用作A2a受體拮抗劑。
本發明還涉及通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物,其治療藉由對A2a受體抑制而改善的病況或病症。
本發明還涉及通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物,其用於治療腫瘤、抑鬱症、認知功能病症、神經退行性病症(帕金森氏病、亨廷頓氏病、阿茲海默症或肌萎縮性側索硬化等)、注意力相關病症、錐體外症候群、異常運動障礙、肝硬化、肝纖維化、脂肪肝、皮膚纖維化、睡眠障礙、中風、腦損傷、神經炎症和成癮行為,較佳腫瘤。
本發明進一步涉及通式(I)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體或其混合物形式,或其醫藥上可接受之鹽,或包含其醫藥組成物,其用於治療腫瘤。
本發明中所述的腫瘤選自黑色素瘤、腦瘤、食管癌、胃癌、肝癌、胰腺癌、結腸直腸癌、肺癌、腎癌、乳腺癌、卵巢癌、前列腺癌、皮膚癌、神經母細胞瘤、肉瘤、骨軟骨瘤、骨瘤、骨肉瘤、精原細胞瘤、睾丸腫瘤、子宮癌、頭頸腫瘤、多發性骨髓瘤、惡性淋巴瘤、真性紅細胞增多 症、白血病、甲狀腺腫瘤、輸尿管腫瘤、膀胱癌、膽囊癌、膽管癌、絨毛膜上皮癌和兒科腫瘤;較佳為肺癌。
含活性成分的醫藥組成物可以是適用於口服的形式,例如片劑、糖錠劑、錠劑、水或油混懸液、可分散粉末或顆粒、乳液、硬或軟膠囊,或糖漿劑或酏劑。可按照本領域任何已知製備藥用組成物的方法製備口服組成物,此類組成物可含有一種或多種選自以下的成分:甜味劑、矯味劑、著色劑和防腐劑,以提供悅目和可口的藥用製劑。片劑含有活性成分和用於混合的適宜製備片劑的無毒的可藥用的賦形劑。這些賦形劑可以是惰性賦形劑,造粒劑、崩解劑,粘合劑,和潤滑劑。這些片劑可以不包衣或可藉由掩蓋藥物的味道或在胃腸道中延遲崩解和吸收,因而在較長時間內提供緩釋作用的已知技術將其包衣。
也可用其中活性成分與惰性固體稀釋劑或其中活性成分與水溶性載體或油溶媒混合的軟明膠膠囊提供口服製劑。
水懸浮液含有活性物質和用於混合的適宜製備水懸浮液的賦形劑。此類賦形劑是懸浮劑,分散劑或濕潤劑。水混懸液也可以含有一種或多種防腐劑、一種或多種著色劑、一種或多種矯味劑和一種或多種甜味劑。
油混懸液可藉由使活性成分懸浮於植物油,或礦物油配製而成。油懸浮液可含有增稠劑。可加入上述的甜味劑和矯味劑,以提供可口的製劑。可藉由加入抗氧化劑保存這些組成物。
藉由加入水可使適用于製備水混懸的可分散粉末和顆粒提供活性成分和用於混合的分散劑或濕潤劑、懸浮劑或一種或多種防腐劑。適宜的分散劑或濕潤劑和懸浮劑可說明上述的例子。也可加入其他賦形劑例如甜味劑、矯味劑和著色劑。藉由加入抗氧化劑例如抗壞血酸保存這些組成物。
本發明的醫藥組成物也可以是水包油乳劑的形式。油相可以是植物油,或礦物油或其混合物。適宜的乳化劑可以是天然產生的磷脂,乳劑也可以含有甜味劑、矯味劑、防腐劑和抗氧劑。此類製劑也可含有緩和劑、防腐劑、著色劑和抗氧劑。
本發明的醫藥組成物可以是無菌注射水溶液形式。可以使用的可接受的溶媒或溶劑有水、林格氏液和等滲氯化鈉溶液。無菌注射製劑可以是其中活性成分溶於油相的無菌注射水包油微乳可藉由局部大量注射,將注射液或微乳注入患者的血流中。或者,最好按可保持本發明化合物恆定循環濃度的方式給予溶液和微乳。為保持這種恆定濃度,可使用連續靜脈內遞藥裝置。這種裝置的實例是Deltec CADD-PLUS.TM.5400型靜脈注射泵。
本發明的醫藥組成物可以是用於肌內和皮下給藥的無菌注射水或油混懸液的形式。可按已知技術,用上述那些適宜的分散劑或濕潤劑和懸浮劑配製該混懸液。無菌注射製劑也可以是在腸胃外可接受的無毒稀釋劑或溶劑中製備的無菌注射溶液或混懸液。此外,可方便地用無菌固定油 作為溶劑或懸浮介質。為此目的,可使用任何調和固定油。此外,脂肪酸也可以製備注射劑。
可按用於直腸給藥的栓劑形式給予本發明化合物。可藉由將藥物與在普通溫度下為固體但在直腸中為液體,因而在直腸中會溶化而釋放藥物的適宜的無刺激性賦形劑混合來製備這些醫藥組成物。
如本領域技術人員所熟知的,藥物的給藥劑量依賴於多種因素,包括但並非限定於以下因素:所用具體化合物的活性、患者的年齡、患者的體重、患者的健康狀況、患者的行為、患者的飲食、給藥時間、給藥方式、排泄的速率、藥物的組合等;另外,最佳的治療方式如治療的模式、通式化合物(I)的日用量或醫藥上可接受之鹽的種類可以如傳統的治療方案來驗證。
除非有相反陳述,在說明書和申請專利範圍中使用的術語具有下述含義。
術語“烷基”指飽和脂肪族烴基團,其為包含1至20個碳原子的直鏈或支鏈基團,較佳含有1至12個碳原子的烷基,更佳含有1至6個碳原子的烷基。非限制性實例包括甲基、乙基、正丙基、異丙基、正丁基、異丁基、第三丁基、第二丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲 基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基,及其各種支鏈異構體等。更佳的是含有1至6個碳原子的低級烷基,非限制性實施例包括甲基、乙基、正丙基、異丙基、正丁基、異丁基、第三丁基、第二丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的,當經取代時,取代基可以在任何可使用的連接點上經取代,所述取代基較佳獨立地視需要選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基和-C(O)OR5中的一個或多個取代基所取代。
術語“烷氧基”指-O-(烷基)和-O-(非取代的環烷基),其 中烷基的定義如上所述。烷氧基的非限制性實例包括:甲氧基、乙氧基、丙氧基、丁氧基、環丙氧基、環丁氧基、環戊氧基、環己氧基。烷氧基可以是視需要取代的或非取代的,當經取代時,取代基較佳為一個或多個以下基團,其獨立地選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基和-C(O)OR5中的一個或多個取代基所取代。
術語“環烷基”指飽和或部分不飽和單環或多環環狀烴取代基,環烷基環包含3至20個碳原子,較佳包含3至12個碳原子,較佳包含3至10個碳原子,更佳包含3至6個碳原子。單環環烷基的非限制性實例包括環丙基、環丁基、環戊基、環戊烯基、環己基、環己烯基、環己二烯基、環庚基、環庚三烯基、環辛基等;多環環烷基包括螺環、稠環和橋環的環烷基。環烷基可以是取代的或非取代的,當經取代時,取代基可以在任何可使用的連接點上經取代,所述取代基較佳獨立地視需要選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基和-C(O)OR5中的一個或多個取代基所取代。
術語“雜環基”指飽和或部分不飽和單環或多環環狀烴取代基,其包含3至20個環原子,其中一個或多個環原子為選自氮、氧或S(O)m(其中m是整數0至2)的雜原子,但不包括-O-O-、-O-S-或-S-S-的環部分,其餘環原子為碳。較佳包含3至12個環原子,其中1~4個是雜原子;更佳 包含3至10個環原子,其中1-4是雜原子;更佳包含5至6個環原子;其中1-3個是雜原子。單環雜環基的非限制性實例包括吡咯烷基、四氫吡喃基、1,2.3.6-四氫吡啶基、哌啶基、哌嗪基、嗎啉基、硫代嗎啉基、高哌嗪基等。多環雜環基包括螺環、稠環和橋環的雜環基。
所述雜環基環可以稠合於芳基、雜芳基或環烷基環上,其中與母體結構連接在一起的環為雜環基,其非限制性實例包括:
雜環基可以是取代的或非取代的,當經取代時,取代基可以在任何可使用的連接點上經取代,所述取代基較佳獨立地視需要選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基和-C(O)OR5中的一個或多個取代基所取代。
術語“芳基”指6至14員全碳單環或稠合多環(也就是共用毗鄰碳原子對的環)基團,其為具有共軛的π電子體系的多環(即其帶有相鄰對碳原子的環)基團,較佳為6至10員,例如苯基和萘基。所述芳基環可以稠合於雜芳基、雜環基或環烷基環上,其中與母體結構連接在一起的環為芳基環,其非限制性實例包括:
芳基可以是取代的或非取代的,當經取代時,取代基可以在任何可使用的連接點上經取代,所述取代基較佳獨立地視需要選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基和-C(O)OR5中的一個或多個取代基所取代。
術語“雜芳基”指包含1至4個雜原子、5至14個環原子的雜芳族體系,其中雜原子選自氧、硫和氮。雜芳基較佳為5至10員,更佳為5員或6員,例如呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、噠嗪基、咪唑基、吡唑基、四唑基等。所述雜芳基環可以稠合於芳基、雜環基或環烷基環上,其中與母體結構連接在一起的環為雜芳基環,其非限制性實例包括:
雜芳基可以是取代的或非取代的,當經取代時,取代基可以在任何可使用的連接點上經取代,所述取代基較佳獨立地視需要選自氫原子、鹵素、烷基、烷氧基、鹵烷基、羥基、羥烷基、氰基、胺基、硝基、環烷基、雜環基、芳基、雜芳基和-C(O)OR5中的一個或多個取代基所取代。
術語“氧代基”指=O。
術語“環烷基氧基”指環烷基-O-。
術語“雜環基烷基”指烷基經一個或多個雜環基取代,其中烷基和雜環基如上所定義。術語“鹵烷基”指烷基經一個或多個鹵素取代,其中烷基如上所定義。
術語“羥基”指-OH。
術語“羥烷基”指經羥基取代的烷基,其中烷基如上所定義。
術語“鹵素”指氟、氯、溴或碘。
術語“胺基”指-NH2。
術語“氰基”指-CN。
術語“硝基”指-NO2。
“視需要”或“視需要地”意味著隨後所描述的事件或環境可以但不必發生,該說明包括該事件或環境發生或不發生地場合。例如,“視需要經烷基取代的雜環基團”意味著烷基可以但不必須存在,該說明包括雜環基團經烷基取代的情形和雜環基團不經烷基取代的情形。
“取代的”指基團中的一個或多個氫原子,較佳為最多5個,更佳為1~3個氫原子彼此獨立地經相應數目的取代基取代。不言而喻,取代基僅處在它們的可能的化學位置,本領域技術人員能夠在不付出過多努力的情況下確定(藉由實驗或理論)可能或不可能的取代。例如,具有游離氫的胺基或羥基與具有不飽和(如烯屬)鍵的碳原子結合時可能是不穩定的。
“醫藥組成物”表示含有一種或多種本文所述化合物或其生理學上/醫藥上可接受之鹽或前體藥物與其他化學組分的混合物,以及其他組分例如生理學/可藥用的載體和賦形劑。醫藥組成物的目的是促進對生物體的給藥,利於活性成分的吸收進而發揮生物活性。
“醫藥上可接受之鹽”是指本發明化合物的鹽,這類鹽用於哺乳動物體內時具有安全性和有效性,且具有應有的生物活性。
其中:R5如通式(I)中所定義。
為了完成本發明的目的,本發明採用如下技術方案:
本發明通式(II)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式,或其醫藥上可接受之鹽的製備方法,包括以下步驟:
通式(IV)的化合物和通式(V)的化合物反應在鹼性條件下,在催化劑存在下發生suzuki偶聯反應得到通式(II)的化合物,其中:提供鹼性條件的試劑包括有機鹼和無機鹼類,所述的有機鹼類包括,但不限於三乙胺、N,N-二異丙基乙胺、正丁基鋰、二異丙基胺基鋰、雙三甲基矽基胺基鋰、醋酸鉀、乙酸鉀、第三丁醇鈉、第三丁醇鉀和正丁醇鈉,所述的無機鹼類包括,但不限於氫化鈉、磷酸鉀、碳酸鈉、碳酸鉀、醋酸鉀、碳酸銫、氫氧化鈉和氫氧化鋰;所述的催化劑包括,但不限於鈀/碳、雷尼鎳、四-三苯基膦鈀、二氯化鈀、醋酸鈀、雙(二亞芐基丙酮)鈀、氯(2-二環己基膦基-2',4',6'-三異丙基-1,1'-聯苯基)[2-(2'-胺基-1,1'-聯苯)]鈀、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀、1,1'-雙(二苄基磷)二氯二戊鐵鈀或三(二亞苄基丙酮)二鈀,較佳為[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀;上述反應較佳在溶劑中進行,所用溶劑包括,但不限於:醋酸、甲醇、乙醇、正丁醇、甲苯、四氫呋喃、二氯甲烷、石油醚、乙酸乙酯、正己烷、二甲基亞碸、1,4-二 氧六環、乙二醇二甲醚、水或N,N-二甲基甲醯胺及其混合物;其中:X為鹵素;W為或環A、環B、G、R1、R3、R6、n和s如通式(II)中所定義。
本發明通式(III)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式,或其醫藥上可接受之鹽的製備方法,包括以下步驟:
第一步,通式(III-1)的化合物和水合肼反應得到通式(III-2)的化合物;第二步,通式(III-2)的化合物和通式(III-3)的化合物反應得到通式(IIIA)的化合物;第三步,通式(IIIA)的化合物和通式(V)的化合物反應在鹼性條件下,在催化劑存在下發生suzuki偶聯反應得到 通式(III)的化合物,其中:提供鹼性條件的試劑包括有機鹼和無機鹼類,所述的有機鹼類包括,但不限於三乙胺、N,N-二異丙基乙胺、正丁基鋰、二異丙基胺基鋰、雙三甲基矽基胺基鋰、醋酸鉀、乙酸鉀、第三丁醇鈉、第三丁醇鉀和正丁醇鈉,所述的無機鹼類包括,但不限於氫化鈉、磷酸鉀、碳酸鈉、碳酸鉀、醋酸鉀、碳酸銫、氫氧化鈉和氫氧化鋰;所述的催化劑包括,但不限於鈀/碳、雷尼鎳、四-三苯基膦鈀、二氯化鈀、醋酸鈀、雙(二亞芐基丙酮)鈀、氯(2-二環己基膦基-2',4',6'-三異丙基-1,1'-聯苯基)[2-(2'-胺基-1,1'-聯苯)]鈀、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀、1,1'-雙(二苄基磷)二氯二戊鐵鈀或三(二亞苄基丙酮)二鈀,較佳為[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀;上述反應較佳在溶劑中進行,所用溶劑包括,但不限於:醋酸、甲醇、乙醇、正丁醇、甲苯、四氫呋喃、二氯甲烷、石油醚、乙酸乙酯、正己烷、二甲基亞碸、1,4-二氧六環、乙二醇二甲醚、水或N,N-二甲基甲醯胺及其混合物;其中:X為鹵素;W為或 環A、環B、R1、R3、R6、n和s如通式(III)中所定義。
本發明通式(III)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式,或其醫藥上可接受之鹽的製備方法,包括以下步驟:
第一步,通式(III-1)的化合物和水合肼反應得到通式(III-2)的化合物;第二步,通式(III-2)的化合物和通式(V)的化合物反應在鹼性條件下,在催化劑存在下發生suzuki偶聯反應得到通式(IIIB)的化合物;第三步,通式(IIIB)的化合物和通式(III-3)的化合物反應得到通式(III)的化合物;其中:提供鹼性條件的試劑包括有機鹼和無機鹼類,所述的有機鹼類包括,但不限於三乙胺、N,N-二異丙基乙胺、正丁基鋰、二異丙基胺基鋰、雙三甲基矽基胺基鋰、醋酸鉀、乙酸鉀、第三丁醇鈉、第三丁醇鉀和正丁醇鈉,所述的無機鹼類包括,但不限於氫化鈉、磷酸鉀、碳酸鈉、碳酸鉀、醋酸鉀、碳酸銫、氫氧化鈉和氫氧化鋰; 所述的催化劑包括,但不限於鈀/碳、雷尼鎳、四-三苯基膦鈀、二氯化鈀、醋酸鈀、雙(二亞芐基丙酮)鈀、氯(2-二環己基膦基-2',4',6'-三異丙基-1,1'-聯苯基)[2-(2'-胺基-1,1'-聯苯)]鈀、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀、1,1'-雙(二苄基磷)二氯二戊鐵鈀或三(二亞苄基丙酮)二鈀,較佳為[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀;上述反應較佳在溶劑中進行,所用溶劑包括,但不限於:醋酸、甲醇、乙醇、正丁醇、甲苯、四氫呋喃、二氯甲烷、石油醚、乙酸乙酯、正己烷、二甲基亞碸、1,4-二氧六環、乙二醇二甲醚、水或N,N-二甲基甲醯胺及其混合物;其中:X為鹵素;W為或環A、環B、R1、R3、R6、n和s如通式(III)中所定義。
本發明通式(III’)所示的化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式,或其醫藥上可接受之鹽的製備方法,包括以下步驟:
第一步,通式(III-1)的化合物和水合肼反應得到通式(III-2)的化合物;第二步,通式(III-2)的化合物和通式(III’a)的化合物反應在鹼性條件下,在催化劑存在下發生suzuki偶聯反應得到通式(III’b)的化合物;第三步,通式(III’b)的化合物和通式(III-3)的化合物反應得到通式(III’)的化合物;其中:提供鹼性條件的試劑包括有機鹼和無機鹼類,所述的有機鹼類包括,但不限於三乙胺、N,N-二異丙基乙胺、正丁基鋰、二異丙基胺基鋰、雙三甲基矽基胺基鋰、醋酸鉀、乙酸鉀、第三丁醇鈉、第三丁醇鉀和正丁醇鈉,所述的無機鹼類包括,但不限於氫化鈉、磷酸鉀、碳酸鈉、碳酸鉀、醋酸鉀、碳酸銫、氫氧化鈉和氫氧化鋰;所述的催化劑包括,但不限於鈀/碳、雷尼鎳、四-三苯基膦鈀、二氯化鈀、醋酸鈀、雙(二亞芐基丙酮)鈀、氯(2-二環己基膦基-2',4',6'-三異丙基-1,1'-聯苯基)[2-(2'-胺基-1,1'-聯苯)]鈀、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀、1,1'-雙(二苄基磷)二氯二戊鐵鈀或三(二亞苄基丙酮)二鈀,較佳為[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀; 上述反應較佳在溶劑中進行,所用溶劑包括,但不限於:醋酸、甲醇、乙醇、正丁醇、甲苯、四氫呋喃、二氯甲烷、石油醚、乙酸乙酯、正己烷、二甲基亞碸、1,4-二氧六環、乙二醇二甲醚、水或N,N-二甲基甲醯胺及其混合物;其中:X為鹵素;W為或環A、R1、R3、R6、n和s如通式(III)中所定義。
以下結合實施例用於進一步描述本發明,但這些實施例並非限制著本發明的範圍。
化合物的結構是藉由核磁共振(NMR)或/和質譜(MS)來確定的。NMR位移(δ)以10-6(ppm)的單位給出。NMR的測定是用Bruker AVANCE-400核磁儀,測定溶劑為氘代二甲基亞碸(DMSO-d 6 ),氘代氯仿(CDCl3),氘代甲醇(CD3OD),內標為四甲基矽烷(TMS)。
MS的測定用FINNIGAN LCQAd(ESI)質譜儀(生產商:Thermo,型號:Finnigan LCQ advantage MAX)。
HPLC的測定使用安捷倫1200DAD高壓液相層析儀(Sunfire C18 150×4.6mm層析柱)和Waters 2695-2996高壓液相層析儀(Gimini C18 150×4.6mm層析柱)。
手性HPLC分析測定使用LC-10A vp(Shimadzu)或者SFC-analytical(Berger Instruments Inc.)。
薄層層析矽膠板使用煙臺黃海HSGF254或青島GF254矽膠板,薄層層析法(TLC)使用的矽膠板採用的規格是0.15mm~0.2mm,薄層層析分離純化產品採用的規格是0.4mm~0.5mm。
柱層析一般使用煙臺黃海矽膠200至300目矽膠為載體。
手性製備柱層析使用Prep Star SD-1(Varian Instruments Inc.)或SFC-multigram(Berger Instruments Inc.)。
CombiFlash快速製備儀使用Combiflash Rf200(TELEDYNE ISCO)。
激酶平均抑制率及IC50值的測定用NovoStar酶標儀(德國BMG公司)。
本發明的已知的起始原料可以採用或按照本領域已知的方法來合成,或可購買自ABCR GmbH & Co.KG,Acros Organics,Aldrich Chemical Company,韶遠化學科技(Accela ChemBio Inc)、達瑞化學品等公司。
實施例中無特殊說明,反應能夠均在氬氣氛或氮氣氛下進行。
氬氣氛或氮氣氛是指反應瓶連接一個約1L容積的氬氣或氮氣氣球。
氫氣氛是指反應瓶連接一個約1L容積的氫氣氣球。
加壓氫化反應使用Parr 3916EKX型氫化儀和清藍QL-500型氫氣發生器或HC2-SS型氫化儀。
氫化反應通常抽真空,充入氫氣,反復操作3次。
微波反應使用CEM Discover-S 908860型微波反應器。
實施例中無特殊說明,溶液是指水溶液。
實施例中無特殊說明,反應的溫度為室溫,為20℃~30℃。
實施例中的反應進程的監測採用薄層層析法(TLC),反應所使用的展開劑,純化化合物採用的柱層析的沖提劑的體系和薄層層析法的展開劑體系包括:A:二氯甲烷/甲醇體系,B:正己烷/乙酸乙酯體系,C:石油醚/乙酸乙酯體系,D:丙酮,E:二氯甲烷/丙酮體系,F:乙酸乙酯/二氯甲烷體系,G:乙酸乙酯/二氯甲烷/正己烷,H:乙酸乙酯/二氯甲烷/丙酮,溶劑的體積比如化合物的極性不同而進行調節,也可以加入少量的三乙胺和醋酸等鹼性或酸性試劑進行調節。
將4-氯-6-苯基嘧啶-2-胺1a(2g,9.75mmol,採用習知的方法“Bioorganic & Medicinal Chemistry Letters,2011,21(8),2497-2501”製備而得)和N-碘代丁二醯亞胺(2.6g,11.7mmol)溶於30mL乙酸中,加畢,反應16小時。反應液中加入200mL飽和碳酸氫鈉,用乙酸乙酯萃取(100mL×3),合併有機相,有機相用飽和氯化鈉溶液洗滌(100mL),無水硫酸鈉乾燥,過濾,收集濾液,濾液減壓濃縮,殘餘物用矽膠層析法以沖提劑體系B純化,得標題化合物1b(2.88g,產率:89%)。
MS m/z(ESI):332.2[M+1]
在氮氣氛下,依次加入化合物1b(2.88g,8.7mmol)、2-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)-6-(三氟甲基)吡啶1c(2.7g,9.17mmol,採用習知的方法 “Journal of Medicinal Chemistry,2012,55(5),1898-1903”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(0.64g,0.87mmol)和碳酸鉀(3.6g,26.1mmol)溶解於66mL 1,4-二氧六環和水(V/V=10:1)的混合溶液中,加熱至83℃,攪拌3小時。停止反應,冷卻至室溫,過濾,濾液中加入200mL乙酸乙酯,再用飽和氯化鈉溶液洗滌(100mL),無水硫酸鈉乾燥,過濾,收集濾液,濾液減壓濃縮,殘餘物用矽膠層析法以沖提劑體系B純化,得標題化合物1d(2.4g,產率:76%)。
MS m/z(ESI):365.4[M+1]
依次加入化合物1d(100mg,0.275mmol)和85%水合肼(62mg,2.747mmol)溶於10mL乙醇中,回流條件下,攪拌反應17小時。停止反應,冷卻至室溫,反應液中加入30mL水,用乙酸乙酯萃取(30mL×3),合併有機相,有機相用飽和氯化鈉溶液洗滌(50mL×2),無水硫酸鈉乾燥,過濾,收集濾液,濾液減壓濃縮,得粗製品標題化合物1e(85mg),其不經純化直接用於下一步反應。
MS m/z(ESI):361.4[M+1]
依次將粗製品1e(85mg,0.275mmol)加入2mL原甲酸(三)乙酯,140℃條件下,攪拌反應0.5小時。停止反應,冷卻至室溫,反應液減壓濃縮,所得殘餘物用高效液相層析法純化,得標題化合物1(6mg,產率:6.9%)。
MS m/z(ESI):371.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.38(s,1H),8.42(brs,2H),7.59(s,1H),7.42(s,1H),7.35-7.31(m,5H),2.48(s,3H)。
將化合物1a(500mg,2.431mmol)和N-溴代丁二醯亞胺(519mg,2.918mmol)溶於16mL N,N-二甲基甲醯胺中,加畢,反應1小時。反應液中加入50mL水,用乙酸乙酯萃取(50mL×3),合併有機相,有機相依次用水(100mL×3)和飽和氯化鈉溶液(200mL)洗滌,無水硫酸鈉乾燥,過濾,收集濾液,濾液減壓濃縮,得粗製品標題化合物2a(698 mg),其不經純化直接用於下一步反應。
MS m/z(ESI):284.2[M+1]
依次將粗製品2a(692mg,2.432mmol)和85%水合肼(1.432mg,24.32mmol)溶於20mL乙醇中,回流條件下,攪拌反應1小時。反應液冷卻至室溫,攪拌反應0.5小時。過濾,濾餅依次用乙醇(3mL×2)和乙醚(3mL×2)洗滌,收集濾餅,濾餅乾燥,得粗製品標題化合物2b(480mg),其不經純化直接用於下一步反應。
MS m/z(ESI):280.3[M+1]
將粗製品2b(480mg,1.713mmol)加入5mL的原甲酸(三)乙酯中,140℃條件下,攪拌反應15分鐘。停止反應,冷卻至室溫,過濾,濾餅依次用乙醇(3mL×3)和乙醚(5mL×3)洗滌,收集濾餅,濾餅乾燥,得標題化合物2c(348mg,產率:62.4%)。
MS m/z(ESI):290.3[M+1]
在氬氣氛下,依次將化合物2c(120mg,0.414mmol)、4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)-1H-吡唑2d(120mg,0.620mmol,採用習知的方法“Journal of the American Chemical Society,2014,136(11),4287-4299”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(30mg,0.041mmol)和碳酸鉀(171mg,1.241mmol)溶解於6mL 1,4-二氧六環和水(V/V=5:1)的混合溶液中,加熱至90℃,攪拌3小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(30mL×3),有機相減壓濃縮,殘餘物高效液相層析法純化,得標題化合物2(33mg,產率:28.7%)。
MS m/z(ESI):278.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 12.79(brs,1H),9.32(s,1H),7.98(brs,2H),7.41-7.37(m,7H)。
在氬氣氛下,依次將化合物2c(100mg,0.345mmol)、6-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)喹啉3a(106mg,0.414mmol,採用習知的方法“Journal of the American Chemical Society,2013,135(50),18730-18733”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.034mmol)和碳酸鉀(143mg,1.034mmol)溶解於6mL 1,4-二 氧六環和水(V/V=5:1)的混合溶液中,加熱至90℃,攪拌2小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(50mL×3),有機相減壓濃縮,殘餘物用矽膠層析法以沖提劑體系A純化,得標題化合物3(49mg,產率:41.9%)。
MS m/z(ESI):339.2[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.38(s,1H),8.88-8.87(m,1H),8.29-8.27(m,1H),8.20(brs,2H),8.05-8.04(m,1H),7.88-7.85(m,1H),7.54-7.50(m,2H),7.37-7.34(m,2H),7.24-7.20(m,3H)。
在氬氣氛下,依次將化合物2c(100mg,0.345mmol)、2-氯-6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶4a(105mg,0.414mmol,採用習知的方法“Organic Syntheses,2005,82,126-133”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.034mmol)和碳酸鉀(143mg,1.034mmol)溶解於10mL 1,4-二氧六環和水(V/V=4:1) 的混合溶液中,加熱至90℃,攪拌3小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(30mL×4),有機相減壓濃縮,殘餘物用高效液相層析法純化,得標題化合物4(20.7mg,產率:17.8%)。
MS m/z(ESI):337.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.36(s,1H),8.38(brs,2H),7.36-7.32(m,5H),7.19-7.14(m,2H),2.35(s,3H)。
在氬氣氛下依次加入6-溴-8-甲基喹啉5b(444mg,2.00mmol,採用習知的方法“Journal of Organic Chemistry,2014,79(11),5379-5385”製備而得)、4,4,4',4',5,5,5',5'-八甲基-2,2'-二(1,3,2-二氧雜環戊硼烷)5a(508mg,2.00 mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(292mg,0.40mmol)和乙酸鉀(588mg,6.00mmol)溶解於10mL乙二醇二甲醚溶液中,加熱至80℃,攪拌12小時。停止反應,冷卻至室溫,過濾,濾液加入20mL乙酸乙酯,依次用水(10mL)洗滌,飽和氯化鈉溶液(10mL)洗滌,用無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用薄層層析法以展開劑體系B純化,得到標題化合物5c(320mg,產率:59.5%)。
MS m/z(ESI):270.1[M+1]
在氬氣氛下,依次將化合物2c(100mg,0.345mmol)、5c(130mg,0.482mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.034mmol)和碳酸鉀(143mg,1.034mmol)溶解於5mL 1,4-二氧六環和水(V/V=4:1)的混合溶液中,加熱至90℃,攪拌2小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(30mL×3),有機相減壓濃縮,殘餘物用高效液相層析法純化,得標題化合物5(32mg,產率:26.4%)。
MS m/z(ESI):353.2[M+1]
1H NMR(400MHz,DMSO-d 6)δ 19.37(s,1H),8.90-8.89(m,1H),8.21-8.19(m,3H),7.78(s,1H),7.51-7.49(m,2H),7.37-7.36(m,2H),7.22-7.20(m,3H),2.60(s,3H)。
在氬氣氛下依次加入5-溴-7-氟-1H-吲唑6a(1.27g,5.90mmol,採用專利申請“WO2012037410”公開的方法製備而得)、化合物5a(2.25g,8.86mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(432mg,0.56mmol)和乙酸鉀(1.74g,17.7mmol)溶解於40mL乙二醇二甲醚溶液中,加熱至80℃,攪拌12小時。停止反應,冷卻至室溫,加入10mL乙酸乙酯,過濾,濾液減壓蒸餾,殘餘物用矽膠層析法以沖提劑體系B純化,得到標題化合物6b(1.178g,產率:76.0%)。
MS m/z(ESI):263.2[M+1]
在氬氣氛下,依次將化合物2c(117mg,0.348mmol)、6b(100mg,0.382mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.035mmol)和碳酸鉀(192mg,1.387mmol)溶解於10mL 1,4-二氧六環和水(V/V=4:1)的混合溶液中,加熱至90℃,攪拌2小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(30mL×3),有機相減壓濃縮,殘餘物用高效液相層析法純化,得標題化合物6(13mg,產率:10.8%)。
MS m/z(ESI):346.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 13.65(brs,1H),9.34(s,1H),8.13-8.11(m,3H),7.55(s,1H),7.35-7.33(m,2H),7.23-7.22(m,3H),7.05-7.02(m,1H)。
在氬氣氛下依次加入6-溴-8-氟喹啉7a(226mg,1.00 mmol,採用習知方法“Journal of Medicinal Chemistry,2010,53(10),4066-4084”製備而得)、化合物5a(305mg,1.20mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(146mg,0.20mmol)和乙酸鉀(294mg,3.00mmol)溶解於10mL乙二醇二甲醚溶液中,加熱至80℃,攪拌12小時。停止反應,冷卻至室溫,過濾,濾液減壓蒸餾,殘餘物用CombiFlash快速製備儀以沖提劑體系B純化,得到標題化合物7b(220mg,產率:80.1%)。
MS m/z(ESI):274.1[M+1]
在氬氣氛下,依次將化合物2c(100mg,0.345mmol)、7b(100mg,0.414mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.034mmol)和碳酸鉀(143mg,1.034mmol)溶解於6mL 1,4-二氧六環和水(V/V=5:1)的混合溶液中,加熱至90℃,攪拌3小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(40mL×4),有機相減壓濃縮,殘餘物用高效液相層析法純化,得標題化合物7(20mg,產率:16.3%)。
MS m/z(ESI):357.2[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.38(s,1H),8.94-8.93(m,1H),8.35-8.33(m,1H),8.26(brs,2H),7.86(s,1H),7.62-7.59(m,1H),7.40-7.36(m,3H),7.26-7.24(m,3H)。
在氬氣氛下依次加入5-溴-4,6-二氯嘧啶-2-胺8a(5g,20.585mmol,採用專利申請“US20100331294”公開的方法製備而得)、4,4,5,5-四甲基-2-(5-甲基呋喃-2-基)-1,3,2-二氧雜戊硼烷8b(4.283g,20.585mmol,採用習知的方法“Organometallics,2015,34(7),1307-1320”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(1.506g,2.058mmol)和碳酸鉀(8.535g,61.756mmol)溶解於150mL 1,4-二氧六環和水(V/V=4:1)的混合溶液中,攪拌2小時。停止反應,反應液中加入200mL水,乙酸乙酯萃取(200mL×3),有機相加入100-200目二氧化矽,減壓濃縮,殘餘物用CombiFlash快速製備儀以沖提劑體系B純化,得標題化合物8c(2.0g,產率:33.7%)。
MS m/z(ESI):288.2[M+1]
依次將化合物8c(1.88g,6.516mmol)和15mL 85%水合肼溶於120mL乙醇中,攪拌反應17小時。停止反應,過濾,乾燥濾餅,得粗製品標題化合物8d(1.5g),其不經純化直接用於下一步反應。
MS m/z(ESI):284.3[M+1]
依次將粗製品8d(1.5g,5.279mmol)加入20mL的原甲酸(三)乙酯中,140℃條件下,攪拌反應15分鐘。停止反應,冷卻至室溫,過濾,濾餅用正己烷洗滌(20mL×2),乾燥,得粗製品標題化合物8e(1.13g,產率:72.8%)。
MS m/z(ESI):294.3[M+1]
在氬氣氛下,依次將粗製品8e(140mg,0.476mmol)、2-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)-6-(三氟甲基)吡啶8f(205mg,0.714mmol,採用習知的方法“Journal of Medicinal Chemistry,2012,55(5),1898-1903”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(35mg,0.048mmol)和碳酸鉀(197mg,1.428mmol)溶解於6mL 1,4-二氧六環和水(V/V=5:1)的混合溶液中,加熱至90 ℃,攪拌2.5小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(50mL×3),有機相減壓濃縮,殘餘物用高效液相層析法純化,得標題化合物8(80mg,產率:44.9%)。
MS m/z(ESI):375.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.30(s,1H),8.26(brs,2H),7.68(s,1H),7.64(s,1H),6.70-6.69(m,1H),6.20-6.19(m,1H),2.60(s,3H),2.03(s,3H)。
在氬氣氛下依次加入5-溴-7-(三氟甲基)-1H-吲唑9a(0.5g,1.88mmol,採用專利申請“WO2012056372”公開的方法製備而得)、化合物5a(575mg,2.26mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(275mg,0.38mmol)和乙 酸鉀(554mg,5.66mmol)溶解於10mL乙二醇二甲醚溶液中,加熱至80℃,攪拌2小時。停止反應,冷卻至室溫,過濾,濾液減壓蒸餾,殘餘物用CombiFlash快速製備儀以沖提劑體系C純化,得到標題化合物9b(270mg,產率:45.9%)。
MS m/z(ESI):313.2[M+1]
在氬氣氛下,依次將化合物2c(117mg,0.348mmol)、9b(35mg,0.11mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.035mmol)和碳酸鉀(192mg,1.387mmol)溶解於5mL 1,4-二氧六環和水(V/V=4:1)的混合溶液中,加熱至90℃,攪拌2小時。停止反應,反應液中加入10mL水,二氯甲烷和甲醇(V/V=8:1)混合溶液萃取(20mL×3),有機相減壓濃縮,殘餘物用高效液相層析法純化,得標題化合物6(10mg,產率:22%)。
MS m/z(ESI):396.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 13.66(s,1H),9.36(s,1H),8.25-8.09(m,4H),7.53(s,1H),7.33-7.31(m,2H),7.25-7.23(m,3H)。
在氬氣氛下,依次將化合物2c(140mg,0.482mmol)、5-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)-1H-吲唑10a(141mg,0.579mmol,採用習知方法“Journal of Medicinal Chemistry,2014,57(9),3856-3873”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(35mg,0.048mmol)和碳酸鉀(200mg,1.448mmol)溶解於12mL 1,4-二氧六環和水(V/V=5:1)的混合溶液中,加熱至90℃,攪拌3小時。停止反應,反應液中加入50mL水,二氯甲烷和水(V/V=8:1)混合溶液萃取(30mL×3),有機相減壓濃縮,殘餘物用高效液相層析法純化,得標題化合物10(8.6mg,產率:5.4%)。
MS m/z(ESI):328.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 13.05(brs,1H),9.33(s,1H),8.05-8.01(m,3H),7.75(s,1H),7.53-7.41(m,1H),7.35-7.33(m,2H),7.20-7.07(m,4H)。
在氬氣氛下,依次將化合物2c(100mg,0.345mmol)、2,6-二甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶11a(91mg,0.414mmol,採用習知的方法“Organic Letters,2009,11(16),3586-3589”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.034mmol)和碳酸鉀(143mg,1.034mmol)溶解於6mL 1,4-二氧六環和水(V/V=5:1)的混合溶液中,加熱至90℃,攪拌3小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(30mL×3),有機相減壓濃縮,殘餘物高效液相層析法純化,得標題化合物11(27mg,產率:24.8%)。
MS m/z(ESI):317.5[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.35(s,1H),8.25(brs,2H),7.32-7.30(m,5H),6.97(s,2H),2.32(s,6H)。
在氬氣氛下,依次將化合物2c(100mg,0.345mmol)、2-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶12a(91mg,0.414mmol,採用習知的方法“Journal of the American Chemical Society,2014,136(11),4133-4136”製備而得)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(25mg,0.034mmol)和碳酸鉀(143mg,1.034mmol)溶解於6mL 1,4-二氧六環和水(V/V=5:1)的混合溶液中,加熱至90℃,攪拌3小時。停止反應,反應液中加入50mL水,乙酸乙酯萃取(30mL×3),有機相減壓濃縮,殘餘物高效液相層析法純化,得標題化合物12(6.8mg,產率:6.5%)。
MS m/z(ESI):303.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.35(s,1H),8.29-8.26(m,3H),7.32-7.25(m,6H),6.99(s,1H),2.39(s,3H)。
氬氣氛下將化合物2c(1.0g,3.45mmol)、氰化鋅(484mg,4.13mmol)、鋅(22mg,0.34mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(124mg,0.17mmol)和三(二亞苄基丙酮)二鈀(156mg,0.17mmol)溶於30mL N,N-二甲基甲醯胺,60℃條件下,反應12小時。反應結束,矽藻土過濾,濾餅用甲醇洗滌,濾液中加入30mL水,二氯甲烷和甲醇(V/V=8:1)混合溶液萃取(30mL×3),合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用矽膠柱層析法以沖提劑A體系純化,得標題化合物13(650mg,產率:80.0%)。
MS m/z(ESI):237.0[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.24(brs,1H),8.83(brs,1H),8.64(s,1H),7.92-7.89(m,2H),7.59-7.57(m,3H)。
將4-氯-6-(4-氯苯基)嘧啶-2-胺14a(11g,38.03mmol,採用專利申請“DE102006008880A1”公開的方法製備而得)和N-溴代丁二醯亞胺(7.11g,39.93mmol)溶於300mL N,N-二甲基甲醯胺中,加畢,攪拌反應2小時。反應液中加入1L水,用乙酸乙酯萃取(300mL×4),合併有機相,有機相依次用水(100mL×3)和飽和氯化鈉溶液(200mL×2)洗滌,無水硫酸鈉乾燥,過濾,收集濾液,濾液減壓濃縮,得粗製品標題化合物14b(12g),產物不經純化直接用於下一步反應。
MS m/z(ESI):318.2[M+1]
依次將粗製品化合物14b(12g,37.62mmol)和40mL 85%水合肼溶於400mL乙醇中,攪拌反應17小時。反應液過濾,濾餅依次用乙醇(50mL)和正己烷(100mL×2)洗滌,收集濾餅,濾餅乾燥,得粗製品標題化合物14c(10.28g),產物不經純化直接用於下一步反應。
MS m/z(ESI):314.3[M+1]
將粗製品化合物14c(2g,6.36mmol)和1.16mL的原甲酸(三)乙酯(1.04g,6.99mmol)加入50mL乙醇中,回流條件下,攪拌反應4小時。反應液冷卻至室溫,減壓濃縮,殘餘物中加入51mL乙醇和正己烷(V/V=1:50)混合溶液攪拌,過濾,收集濾餅,得標題化合物14d(2g,產率:96.9%)。
MS m/z(ESI):324.3[M+1]
氬氣氛下,依次將化合物14d(250mg,770.27μmol)、化合物1c(265.36mg,924.32μmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(56.36mg,77.03μmol)、碳酸鉀(319.36mg,2.31mmol)加入10mL 1,4-二氧六環和水(V/V=4:1)的混合溶劑中,加熱至90℃,攪拌2小時。反應液冷卻至室溫,減壓濃縮,殘餘物用CombiFlash快速製備儀以沖提劑體系B純化,所得粗製品用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物14(64.4mg,產率:20.7%)。
MS m/z(ESI):405.5[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.39(s,1H),8.46(brs,2H),7.58(s,1H),7.49(s,1H),7.43-7.35(m,4H),2.50(s, 3H)。
在氬氣氛下,依次將4,6-二氯嘧啶-2-胺15a(10g,60.98mmol,阿達馬斯試劑有限公司)、(4-氟苯基)硼酸15b(8.53g,60.98mmol,韶遠科技上海有限公司)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(4.46g,6.10mmol)和碳酸鉀(16.83g,121.96mmol)加入250mL 1,4-二氧六環和水(V/V=4:1)的混合溶劑中,加熱至60℃,攪拌3小時。反 應液冷卻至室溫,加入300mL水,用乙酸乙酯(150mL×3)萃取,合併有機相,有機相減壓濃縮,殘餘物用矽膠層析法以沖提劑體系B純化,得到標題化合物15c(11.0g,產率:76.0%)。
MS m/z(ESI):224.3[M+1]
將化合物15c(11.0g,49.19mmol)溶於100mL N,N-二甲基甲醯胺中,分批加入N-溴代丁二醯亞胺(8.75g,49.19mmol),攪拌1小時。反應液中加入400mL水,用乙酸乙酯萃取(100mL×3),合併有機相,有機相依次用水(100mL×3)和飽和氯化鈉溶液(200mL)洗滌,無水硫酸鈉乾燥,過濾,收集濾液,濾液減壓濃縮,得粗製品標題化合物15d(6.0g),產品不經純化直接用於下一步反應。
MS m/z(ESI):301.9[M+1]
依次將粗製品化合物15d(5.5g,18.18mmol)和10mL 85%水合肼溶於20mL乙醇中,回流條件下,攪拌反應1小時。反應液冷卻至室溫,攪拌反應0.5小時。過濾,濾餅依次用乙醇(3mL×2)和乙醚(3mL×2)洗滌,收集濾餅,真空乾燥,得粗製品標題化合物15e(4.4g),產品不經純化直接用於下一步反應。
MS m/z(ESI):298.1[M+1]
依次將粗製品化合物15e(500mg,1.68mmol)和原甲酸(三)乙酯(497mg,3.35mmol)加入20mL乙醇中,回流3小時。反應液冷卻至室溫,過濾,濾餅2mL乙醇洗滌一次,收集濾餅,得粗製品標題化合物15f(460mg),產物不經純化直接下一步反應。
MS m/z(ESI):307.9[M+1]
氬氣氛下,將粗製品化合物15f(120mg,389.47μmol)、化合物4a(138.24mg,545.26μmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(28.50mg,38.95μmol)、碳酸鉀(161.48mg,1.17mmol)加入6.0mL 1,4-二氧六環和水(V/V=5:1)的混合溶劑中,加熱至90℃,攪拌2小時。反應液冷卻至室溫,加入50mL水,用乙酸乙酯萃取(30mL×3),合併有機相,有機相減壓濃縮,殘餘物用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物15(22mg,產率:15.9%)。
MS m/z(ESI):355.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.35(s,1H),8.38(brs,2H),7.40-7.37(m,2H),7.20-7.18(m,4H),2.37(s,3H)。
氬氣氛下,依次將化合物15f(100mg,324.56μmol)、化合物1c(111.81mg,389.47μmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(23.73mg,32.46μmol)、碳酸鉀(89.71mg,649.12μmol)加入6.0mL 1,4-二氧六環和水(V/V=5:1)的混合溶劑中,加熱至90合,攪拌2小時。反應液冷卻至室溫,加入20mL水,用乙酸乙酯萃取(10mL×3),合併有機相,有機相減壓濃縮,殘餘物用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物16(34mg,產率:26.9%)。
MS m/z(ESI):389.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.35(s,1H),8.40(brs,2H),7.56(s,1H),7.43(s,1H),7.34-7.37(m,2H),7.13-7.17(m,2H),2.49(s,3H)。
依次將2-(甲硫基)-6-苯基嘧啶-4-胺17a(1.2g,5.5mmol,採用習知的方法“Chemical & Pharmaceutical Bulletin,1981,29(4),948-54”)和N-溴代丁二醯亞胺(1.1g,6.1mmol)加入20mL N,N-二甲基甲醯胺中,攪拌反應1小時。加入水,用乙酸乙酯萃取3次,合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,得粗製品標題化合物17b(550mg),產物不經純化直接用於下一步反應。
MS m/z(ESI):296.0[M+1]
將粗製品化合物17b(250mg,0.84mmol)溶於10mL 1,4-二氧六環,滴加氯乙醛(249mg,1.27mmol),90℃條 件下,攪拌36小時。反應液冷卻至室溫,加入飽和碳酸氫鈉溶液,用乙酸乙酯萃取3次,合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用薄層層析法以展開劑體系A純化,得標題化合物17c(195mg,產率:72%)。
MS m/z(ESI):320.1[M+1]
將化合物17c(195mg,0.61mmol)溶於10mL二氯甲烷中,分批加入間氯過氧苯甲酸(316mg,1.83mmol),攪拌反應3小時。反應液中加入飽和碳酸氫鈉溶液,用乙酸乙酯萃取3次,合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,得粗製品標題化合物17d(210mg),產物不經純化直接用於下一步反應。
MS m/z(ESI):352.1[M+1]
將粗製品化合物17d(210mg,0.59mmol)溶於10mL 1,4-二氧六環,滴加1mL 30%胺水,攪拌反應1小時。反應液中加入水,用二氯甲烷和甲醇(V/V=10:1)混合溶液萃取3次,合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用薄層層析法以展開劑體系A純化,得標題化合物17e(172mg,產 率:46%)。
MS m/z(ESI):289.1[M+1]
氬氣氛下,依次將化合物17e(80mg,0.28mmol)、化合物1c(95mg,0.332mmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(20mg,28μmol)、碳酸鉀(87mg,0.56mmol)加入10mL 1,4-二氧六環和水(V/V=4:1)的混合溶劑中,加熱至90℃,攪拌3小時。反應液冷卻至室溫,加入水,用二氯甲烷和甲醇(V/V=8:1)混合溶液萃取3次,合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用薄層層析法以展開劑體系A純化,得標題化合物17(15mg,產率:14%)。
MS m/z(ESI):370.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 8.02(s,1H),7.99(brs,2H),7.57(s,1H),7.55(s,1H),7.43(s,1H),7.30(brs,5H),2.45(s,3H)。
在氬氣氛下,依次將化合物15a(11g,63.72mmol)、(2,4-二氟苯基)硼酸18a(10.06g,63.72mmol,上海書亞科技有限公司)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(4.66g,6.37mmol)和碳酸鉀(26.42g,191.17mmol)加入500mL 1,4-二氧六環和水(V/V=4:1)的混合溶劑中,90℃條件下,攪拌反應2小時。反應液過濾,濾液分液,水相用乙酸乙酯萃取(200mL×2),合併有機相,減壓濃縮,殘餘物用矽膠層析法以沖提劑體系B純化,得標題化合物18b(14.04g,產率:91.2%)。
MS m/z(ESI):242.3[M+1]
將化合物18b(14.04g,58.11mmol)溶於300mL的N,N-二甲基甲醯胺中,加入N-溴代丁二醯亞胺(11.38g, 63.92mmol),攪拌反應1小時。反應液倒入1L水中,攪拌30分鐘,過濾,收集濾餅,真空乾燥,得粗製品標題化合物18c(16g),產品不經純化直接進行下一步反應。
MS m/z(ESI):320.0[M+1]
將粗製品化合物18c(16g,49.92mmol)溶於250mL乙醇中,加入50mL 85%水合肼,攪拌反應17小時。反應液過濾,濾餅依次用乙醇(20mL×2)、正己烷(20mL×2)洗滌,乾燥濾餅,得標題化合物18d(12g,產率:76.1%)。
MS m/z(ESI):316.0[M+1]
將化合物18d(4g,12.65mmol)和原甲酸(三)乙酯(2.25g,15.18mmol)溶解於50mL乙醇中,回流條件下,攪拌反應2小時。停止反應,冷卻至室溫,反應液減壓濃縮,所得殘餘物用5mL乙醇打漿0.5小時,過濾,濾餅用無水乙醚(10mL×2)洗滌,乾燥濾餅,得標題化合物18e(3.85g,產率:93.4%)。
MS m/z(ESI):326.2[M+1]
氬氣氛下,依次將化合物18e(110mg,337.32μmol)、 化合物1c(145.26mg,505.98μmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(24.7mg,33.73μmol)、碳酸鉀(93.1mg,674.64μmol)加入12mL 1,4-二氧六環和水(V/V=5:1)的混合溶劑中,加熱至90℃,攪拌3小時。反應冷卻至室溫,加入水,用乙酸乙酯萃取(20mL×3),合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物18(31mg,產率:22.6%)。
MS m/z(ESI):407.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.41(s,1H),8.50(brs,2H),7.55(brs,2H),7.44(s,1H),7.20-7.18(m,2H),2.49(s,3H)。
將4-氯-6-(2-氟苯基)嘧啶-2-胺19a(1.5g,6.71mmol,採用專利申請的公開的方法“WO 2014162039A1”製備而得)溶於20mL的N,N-二甲基甲醯胺中,加入N-溴代丁二醯亞胺(1.31g,7.38mmol),攪拌反應1小時。反應液中加入120mL水,攪拌,過濾,收集濾餅,真空乾燥,得粗製品標題化合物19b(1.9g),產品不經純化直接進行下一步反應。
MS m/z(ESI):301.9[M+1]
將粗製品化合物19b(1.9g,6.28mmol)溶於30mL乙醇中,加入85%水合肼(125.61mmol,7.18mL),60℃條件下,攪拌1小時。反應液過濾,濾餅用乙醇(20mL×2)洗滌,乾燥濾餅,得標題化合物19c(1.7g,產率:90.8%)。
MS m/z(ESI):297.8[M+1]
將化合物19c(1.7g,5.70mmol)加入10mL原甲酸(三)乙酯中,130℃條件下,攪拌0.5小時。反應液冷卻至室溫,過濾,濾餅中加入乙酸乙酯,攪拌,過濾,乾燥濾餅,得標題化合物19d(1.1g,產率:62.6%)。
MS m/z(ESI):307.9[M+1]
氬氣氛下,依次將化合物19d(200mg,649.12μmol)、化合物11a(151.32mg,649.12μmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(47.45mg,64.91μmol)、碳酸鉀(179.16mg,1.30mmol)加入12mL 1,4-二氧六環和水(V/V=5:1)的混合溶劑中,加熱至80℃,攪拌3小時。反應液冷卻至室溫,加入水,用乙酸乙酯萃取(20mL×3),合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物19(26mg,產率:12%)。
MS m/z(ESI):335.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.38(s,1H),8.30(s,2H),7.41(brs,2H),7.19-7.22(m,1H),7.09-7.13(m,1H),6.91(s,2H),2.29(s,6H)。
氬氣氛下,依次將2-(二氟甲基)-6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶20a(247.56mg,919.96μmol,採用專利申請“WO2011095625A1”公開的方法製備而得)、化合物18e(200mg,613.31μmol)、[1,1'-雙(二苯基膦基)二茂鐵]二氯化鈀(44.88mg,61.33μmol)、碳酸鉀(254.29mg,1.84mmol)加入12mL 1,4-二氧六環和水(V/V=5:1)的混合溶劑中,加熱至90℃,攪拌2小時。反應液冷卻至室溫,減壓濃縮,殘餘物用CombiFlash快速製備儀以沖提劑體系B純化,所得粗製品用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物20(26mg,產率:12%)。
MS m/z(ESI):389.5[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.40(s,1H),8.44(brs,2H),7.54(s,1H),7.40-7.18(m,4H),6.96-6.69(m,1H),2.44(s,3H)。
將4-氯-2-甲硫基-6-苯基-嘧啶21a(1.5g,6.34mmol,採用習知的方法“Tetrahedron,1994,50(34),10299-308”製備而得)溶於40mL乙腈中,加入2-胺基丙-1-醇(713.91mg,9.50mmol)和N,N-二異丙基乙胺(1.64g,12.67mmol),75℃條件下,反應72小時。反應液減壓濃縮,殘餘物用矽膠柱層析法以沖提劑體系A純化,得標題化合物21b(1.5g,產率:86%)。
MS m/z(ESI):276.2[M+1]
將化合物21b(1.5g,5.45mmol)溶於30mL N,N-二甲 基甲醯胺中,分批加入N-溴代丁二醯亞胺(969.50mg,5.45mmol),攪拌反應1小時。加入150mL水,用二氯甲烷和甲醇混合溶液(V/V=8:1)萃取3次,合併有機相,依次用水、飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用矽膠柱層析法以沖提劑體系A純化,得標題化合物21c(1.2g,產率:62.2%)。
MS m/z(ESI):354.1[M+1]
將化合物21c(2.3g,6.49mmol)溶於40mL二氯甲烷中,加入三乙胺(983.59mg,9.74mmol),滴加甲磺醯氯(892.44mg,7.79mmol),攪拌過夜。加入飽和碳酸氫鈉溶液,二氯甲烷萃取三次(30mL×3),合併有機相,飽和氯化鈉洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用矽膠柱層析法以沖提劑體系A純化,得標題化合物21d(1.2g,產率:55%)。
MS m/z(ESI):336.0[M+1]
將化合物21d(1.2g,3.57mmol)加入1,4二氧六環中,加入二氧化錳(3.14g,35.69mmol),90℃條件下,反應36小時。反應液冷卻至室溫,墊矽藻土過濾,濾餅用甲醇洗滌,濾液減壓濃縮,殘餘物用矽膠柱層析法以沖提 劑體系A純化,得標題化合物21e(750mg,產率:62.9%)。
MS m/z(ESI):334.1[M-1]
將化合物21e(320mg,957.41μmmol)溶於5mL三氟乙酸,滴加過氧化氫(0.5mL 957.41μmmol),攪拌1小時。反應液用飽和碳酸鈉溶液中和,二氯甲烷萃取(30mL×3),合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,得到粗製品化合物21f(350mg),產物不經純化直接用於下一步反應。
將粗製品化合物21f(350mg,955.68μmmol)溶於10mL 1,4-二氧六環,加入一水合胺(1.0mL,955.68μmmol,),40℃條件下,反應1小時。反應液減壓濃縮,加入水,二氯甲烷和甲醇混合溶液(V/V=8:1)萃取三次,合併有機相,有機相用飽和氯化鈉溶液洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用薄層層析法以展開劑體系A純化,得標題化合物21g(215mg,產率:74.2%)。
氬氣氛下,依次將化合物21g(215mg,709.20μmmol)、化合物11a(247.99mg,1.06mmol)、[1,1'-雙(二 苯基膦基)二茂鐵]二氯化鈀(51.84mg,70.92μmmol)、碳酸氫鈉(131.06mg,1.56mmol)加入12mL 1,4-二氧六環和水(V/V=5:1)的混合溶劑中,加熱至80℃,攪拌2小時。反應液冷卻至室溫,加入水,乙酸乙酯萃取(20mL×3),合併有機相,飽和氯化鈉溶液洗滌,硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物21(45mg,產率:19.3%)。
MS m/z(ESI):330.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 7.68(s,1H),7.65(s,2H),7.28(s,2H),7.24(s,3H),6.89(s,2H),2.31(s,6H),2.27(s,3H)。
將2-(氯甲基)-6-甲基吡啶22b(1g,7.06mmol)和碳酸鉀(1.46g,10.59mmol)溶於40mL乙腈,加入1-甲基哌嗪22a(848.57mg,8.47mmol,939.72uL),80℃條件下,反應17小時。反應液用矽膠柱層析法以沖提劑體系A純化,得標題化合物22c(1g,產率:69%)。
MS m/z(ESI):206.4[M+1]
氬氣氛下,將化合物22c(1g,4.87mmol)、化合物5a(146.13μmmol)、甲氧基(環辛二烯)銥(I)二聚體(78.44mg,292.26μmmol)溶於40mL正己烷。80℃條件下,反應17小時。反應液減壓濃縮,反應液用矽膠柱層析法以沖提劑體系B純化,得標題化合物22d(217mg,產率:13.5%)。
採用實施例5合成途徑,將第一步原料5b替換為22d,製得標題化合物22(27.6mg)。
MS m/z(ESI):415.5[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.34(s,1H),8.26(brs,2H),7.32-7.28(m,6H),6.85(s,1H),3.38(s,2H),2.54(s,3H),2.43(s,3H),2.19-2.09(m,8H)。
採用實施例4合成途徑,將第一步原料化合物4a替換為2-氯-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)-6-(三氟甲基)吡啶23a(採用習知的方法“Research on Chemical Intermediates,2013,39(4),1917-1926”製備而得),製得標題化合物23(11.8mg)。
MS m/z(ESI):391.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.40(s,1H),8.58(brs,2H),7.82(s,1H),7.65(s,1H),7.40-7.36(m,5H)。
採用實施例17合成途徑,將第五步原料化合物1c替換為化合物4a,製得標題化合物24(32mg)。
MS m/z(ESI):336.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 8.00(s,1H),7.93(s,2H),7.55(s,1H),7.31(s,5H),7.14(d,2H),2.33(s,3H)。
採用實施例4合成途徑,將第一步原料化合物4a替換為2-甲氧基-6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶25a(採用習知的方法“Chemistry-A European Journal,2017,23(24),5663-5667”製備而得),製得標題化合物25(11.8mg)。
MS m/z(ESI):333.2[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.33(s,1H),8.24(brs,2H),7.36-7.29(m,5H),6.76(s,1H),6.48(s,1H),3.77(s,3H),2.29(s,3H)。
在氬氣氛下,依次加入2-乙基-6-甲基吡啶26a(1g,8.25mmol,韶遠科技上海有限公司)、化合物5a(2.31g,9.08mmol)、(1Z,5Z)-cycloocta-1,5-diene;iridium;methyloxonium(164.10mg,247.57μmmol)和4-第三丁基-2-(4-第三丁基-2-吡啶基)吡啶(588mg,6.00mmol)於40mL正己烷溶液中,加熱至80℃,攪拌17小時。反應液減壓濃縮,殘餘物用矽膠柱層析法以沖提劑體系B純化,得到2-乙基-6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶26b(809mg,產率:39.7%)。
MS m/z(ESI):248.2[M+1]
採用實施例4合成途徑,將第一步原料化合物4a替換為26b,製得標題化合物26(136.6mg)。
MS m/z(ESI):331.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.35(s,1H),8.25(brs,2H),7.32-7.28(m,5H),7.12(s,1H),6.80(s,1H),2.57-2.55(m,2H),2.37(s,3H),1.03-1.00(m,3H)。
採用實施例19合成途徑,將第四步原料化合物11a替換為化合物4a,製得標題產物27(73mg)。
MS m/z(ESI):355.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 8.39(s,1H),8.44(s,2H),7.49-7.45(m,2H),7.28-7.24(m,1H),7.17-7.14(m,2H),7.11(s,1H),2.33(s,3H)。
採用實施例15合成途徑,將第五步原料化合物4a替換為化合物11a,製得標題產物28(38mg)。
MS m/z(ESI):335.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.34(s,1H),8.24(brs,2H),7.39-7.35(m,2H),7.16-7.11(m,2H),6.95(s,2H),2.33(s,6H)。
採用實施例15合成途徑將第一步原料化合物15b替換為(3-氟苯基)硼酸29a,得到化合物8-溴-7-(3-氟苯基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺29b; 將實施例15的第五步原料化合物4a替換為化合物1c,製得標題化合物29(28mg)。
MS m/z(ESI):389.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.39(s,1H),8.46(brs,2H),7.60(s,1H),7.48(s,1H),7.36-7.34(m,1H),7.23-7.19(m,2H),7.10-7.08(m,1H),2.49(s,3H)。
採用實施例11合成途徑,將第一步原料化合物11a替換為2-環丙基-6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶30a(採用專利申請“WO2011070131A1”公開的方法製備而得),製得標題化合物30(43mg)。
MS m/z(ESI):343.2[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.34(s,1H),8.23(brs,2H),7.47-7.31(m,5H),6.92-6.87(m,2H),2.28(s,3H),1.98-1.90(m,1H),0.84-0.72(m,4H)。
採用實施例17合成途徑,將第五步原料化合物1c替換為化合物11a,值得標題化合物31(40mg)。
MS m/z(ESI):316.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 8.00(s,1H),7.99(s,2H),7.51(d,1H),7.31-7.29(m,2H),7.26-7.25(m,3H),6.91(s, 2H),2.30(s,6H)。
氬氣氛下,將6-氯-2-(甲硫基)嘧啶-4-胺32a(2.0g,11.39mmol,上海畢得科技有限公司)和(4-氟苯基)硼酸(2.39g,17.08mmol)溶於50mL甲苯中,依次加入四(三苯基膦)鈀(657.60mg,569.35μmmol)和碳酸鈉(2.41g,22.77mmol)和10mL水。90℃,攪拌3小時。加入水,乙酸乙酯萃取三次(50mL×3),合併有機相,飽和氯化鈉洗滌,無水硫酸鈉乾燥,過濾,濾液減壓濃縮,殘餘物中加入甲醇攪拌,過濾,收集濾餅,得6-(4-氟苯基)-2-(甲硫基)嘧啶-4-胺32b(1.3g,產率:48.5%)。
採用實施例17合成途徑,第一步原料化合物17a替換為化合物32b,製得8-溴-7-(4-氟苯基)咪唑并[1,2-c]嘧啶-5-胺32c; 將實施例17的第五步原料化合物1c替換為化合物11a,製得標題化合物32(70mg)。
MS m/z(ESI):334.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 7.98(d,1H),7.82(s,2H),7.52(d,1H),7.35-7.32(m,2H),7.28-7.08(m,2H),6.92(s,2H),2.32(s,6H)。
採用實施例19的合成途徑,將第四步原料化合物11a替換為化合物1c,製得標題化合物33(25mg)。
MS m/z(ESI):389.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.43(s,1H),8.48(brs,2H),7.55(s,1H),7.50-7.44(m,2H),7.42(s,1H),7.28-7.26(m,1H),7.15-7.12(m,1H),2.46(s,3H)。
採用實施例18合成途徑,將第五步原料化合物1c替換為化合物4a,製得標題化合物34(30.4mg)。
MS m/z(ESI):373.3[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.39(s,1H),8.46(brs,2H),7.55-7.54(m,1H),7.25-7.14(m,4H),2.36(s,3H)。
採用實施例15合成途徑,將第一步原料化合物15b替換為對甲苯基硼酸35a(上海達瑞化學有限公司),製得8-溴-7-(p-甲苯基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺35b;將實施例15第五步原料化合物15f替換為化合物 35b,製得標題化合物35(21.3mg)。
MS m/z(ESI):351.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.34(s,1H),8.33(brs,2H),7.26-7.13(m,6H),2.36(s,3H),2.30(s,3H)。
採用實施例14合成途徑,將第四步原料化合物1c替換為化合物4a,製得標題化合物36(45.9mg)。
MS m/z(ESI):371.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.36(s,1H),8.40(brs,2H),7.43-7.35(m,4H),7.20-7.18(m,2H),2.38(s,3H)。
採用實施例2合成途徑,將第四步原料化合物2d替 換為4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶37a(上海畢得醫藥科技有限公司),製得標題化合物37(20mg)。
MS m/z(ESI):289.0[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.35(s,1H),8.47-8.46(m,2H),8.29(brs,2H),7.33-7.29(m,7H)。
採用實施例2合成途徑,將第四步原料化合物2d替換為2-氯-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶38a(阿達馬斯試劑有限公司),製得標題化合物38(20mg)。
MS m/z(ESI):323.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.36(s,1H),8.40(brs,2H),8.28-8.27(m,1H),7.47(s,1H),7.38-7.31(m,5H),7.23-7.22(m,1H)。
採用實施例18合成途徑,將第五步原料1c替換為2-氯-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)-6-(三氟甲基)吡啶(採用習知的方法“Research on Chemical Intermediates,2013,39(4),1917-1926”製備而得),製得標題化合物39(19.8mg)。
MS m/z(ESI):427.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.66(s,1H),8.80(brs,2H),7.80(s,1H),7.70(s,1H),7.65-7.59(m,1H),7.29-7.22(m,2H)。
採用實施例18合成途徑,將第五步原料1c替換為化合物11a,製得標題化合物40(40mg)。
MS m/z(ESI):353.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.54(s,1H),8.43(brs, 2H),7.51-7.45(m,1H),7.21-7.10(m,2H),6.92(s,2H),2.31(s,6H)。
採用實施例18合成途徑,將第五步原料1c替換為化合物25a,製得標題化合物41(10.6mg)。
MS m/z(ESI):369.5[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.37(s,1H),8.33(brs,2H),7.50-7.48(m,1H),7.22-7.13(m,2H),6.76(s,1H),6.45(s,1H),3.76(s,3H),2.30(s,3H)。
採用實施例1合成途徑,將第四步原料原甲酸(三)乙酯替換為原乙酸三乙酯,製得標題化合物42(52mg)。
MS m/z(ESI):385.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 7.69(brs,2H),7.55(s,1H),7.41(s,1H),7.35-7.31(m,5H),2.96(s,3H),2.46(s,3H)。
採用實施例4合成途徑,將第一步原料化合物4a替換為1-異丙基-5-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶-2(1H)-酮43a(採用專利申請公開的方法“WO2011143426A1”製備而得),製得標題化合物43(31mg)。
MS m/z(ESI):347.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.33(s,1H),8.13(brs,2H),7.47-7.33(m,7H),6.38-6.35(m,1H),4.97-4.90(m,1H),0.99-0.97(m,6H)。
採用實施例18合成途徑,將第五步原料1c替換為化合物30a,製得標題化合物44(79.4mg)。
MS m/z(ESI):379.5[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.38(s,1H),8.33(brs,2H),7.52-7.46(m,1H),7.21-7.11(m,2H),6.90-6.85(m,2H),2.28(s,3H),1.95-1.85(m,1H),0.85-0.83(m,2H),0.72-0.70(m,2H)。
採用實施例18合成途徑,將第五步原料1c替換為化合物12a,製得標題化合物45(79.4mg)。
MS m/z(ESI):339.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.46(s,1H),8.40(brs,2H),8.31-8.30(m,1H),7.53-7.47(m,1H),7.22-7.11(m,3H),6.98-6.97(m,1H),2.39(s,3H)。
採用實施例15合成途徑,將第一步原料化合物15b替換為(2-氯-4-氟苯基)硼酸(韶遠科技上海有限公司),製得8-溴-7-(2-氯-4-氟苯基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺46a;將實施例15的第五步原料化合物4a替換為化合物1c,製得標題化合物46(32mg)。
MS m/z(ESI):423.3[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.43(s,1H),8.54(brs,2H),7.54(s,1H),7.53-7.49(m,2H),7.47(s,1H),7.40-7.28(m,1H),2.47(s,3H)。
採用實施例22合成途徑,將原料化合物22c替換為4-((6-氯吡啶-2-基)甲基)嗎啉(採用專利申請“US20150361100A1”公開的方法製備而得),製得標題化合物47(34.8%)。
MS m/z(ESI):422.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.37(s,1H),7.58(s,1H),7.48-7.33(m,5H),7.05(s,1H),3.35-3.28(m,6H),2.11(s,2H),1.90-1.87(m,4H)。
採用實施例43合成途徑,將第一步原料化合物43a替換為嗎啉48a,製得標題化合物48(30.8mg)。
MS m/z(ESI):402.5[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.34(s,1H),8.23(brs,2H),7.35-7.28(m,6H),6.85(s,1H),3.42-3.35(m,6H), 2.44(s,3H),2.13-2.05(m,4H)。
採用實施例15合成途徑,將第一步原料化合物15b替換為(4-氯-2-氟苯基)硼酸(韶遠科技上海有限公司),製得8-溴-7-(4-氯-2-氟苯基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺49a;將實施例15的第五步原料化合物4a替換為化合物1c,製得標題化合物49(20mg)。
MS m/z(ESI):422.7[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.43(s,1H),8.54(brs,2H),7.56-7.52(m,2H),7.45(s,1H),7.42-7.38(m,2H),2.48(s,3H)。
採用實施例15合成途徑,將第一步原料化合物15b替換為(4-氯-2-氟苯基)硼酸(韶遠科技上海有限公司),製得標題化合物50(30mg)。
MS m/z(ESI):389.4[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.41(s,1H),8.47(brs,2H),7.54-7.50(m,1H),7.44-7.39(m,2H),7.18(s,1H),7.14(s,1H),2.36(s,3H)。
氬氣氛下,依次將化合物15f(1.00g,3.25mmol)、化合物20a(1.05g,3.90mmol)、[1,1'-雙(二苯基膦基)二 茂鐵]二氯化鈀(238mg,324.6μmol)、碳酸氫鈉(682mg,8.11mmol)加入55mL 1,4-二氧六環和水(V/V=9:2)的混合溶劑中,加熱至95℃,攪拌17小時。反應液冷卻至室溫,過濾,濾液減壓濃縮,殘餘物用高效液相色製備(Waters 2767-SQ Detecor2,沖提體系:碳酸氫銨,水,乙腈)純化,得標題化合物51(50mg)。
MS m/z(ESI):371.2[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.37(s,1H),8.38(brs,2H),7.44(s,1H),7.39-7.36(m,2H),7.32(s,1H),7.19-7.14(m,2H),6.98-6.70(m,1H),2.46(s,3H)。
採用實施例14合成途徑,將原料化合物1c替換為化合物20a,製得標題化合物52(32mg)。
MS m/z(ESI):387.0[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.37(s,1H),8.39(brs,2H),7.40-7.43(m,2H),7.33-7.38(m,4H),6.84(t,1H),2.46(s,3H)。
採用實施例14合成途徑,將原料化合物1c替換為化合物2-(氟甲基)-6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧雜戊硼烷-2-基)吡啶53a(採用專利申請“WO201195625A1”公開的方法製備而得),製得標題化合物53(4mg)。
MS m/z(ESI):369.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.36(s,1H),8.36(brs,2H),7.42-7.32(m,3H),7.19(s,1H),5.42-5.30(m,2H),7.19-7.14(m,2H),2.40(s,3H)。
採用實施例14合成途徑,將原料化合物1c替換為化合物11a,製得標題化合物54(47.5mg)。
MS m/z(ESI):351.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.34(s,1H),8.27(brs,2H),7.39-7.33(m,4H),6.96(s,2H),2.34(s,6H)。
採用實施例15合成途徑,將原料化合物4a替換為化台物53a,製得標題化合物55(20mg)。
MS m/z(ESI):353.2[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.36(s,1H),8.31(brs,2H),7.40-7.36(m,2H),7.20-7.13(m,4H),5.42-5.31(m,2H),2.41(s,3H)。
採用實施例19合成途徑,將原料化合物11a替換為化合物20a,製得標題化合物56(105.6mg)。
MS m/z(ESI):371.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.53(s,1H),8.50(brs,2H),7.47-7.42(m,2H),7.37(s,1H),7.31(s,1H),7.26-7.24(m,1H),7.13-7.11(m,1H),6.94-6.66(m,1H),2.41(s,3H)。
採用實施例19合成途徑,將原料化合物11a替換為化合物53a,製得標題化合物57(58mg)。
MS m/z(ESI):353.2[M+1]
1H NMR(400MHz,METHANOL-d 4)δ 9.29(s,1H),7.51-7.48(m,1H),7.43-7.41(m,1H),7.26-7.21(m,3H),7.04-6.99(m,1H),5.37-5.25(m,2H),2.45(s,3H)。
採用實施例18合成途徑,將原料化合物1c替換為化合物53a,製得標題化合物58(30mg)。
MS m/z(ESI):371.1[M+1]
1H NMR(400MHz,CD3OD)δ 9.29(s,1H),7.59-7.55(m,1H),7.27-7.25(m,2H),7.06-7.02(m,1H),6.91-6.86(m,1H),5.40-5.28(m,2H),2.48(s,3H)。
採用實施例49合成途徑,將原料化合物1c替換為化合物20a,製得標題化合物59(49.1mg)。
MS m/z(ESI):405.1[M+1]
1H NMR(400MHz,DMSO-d 6)δ 9.42(s,1H),7.54-7.50(m, 1H),7.40-7.30(m,4H),6.97-6.69(m,1H),3.43(brs,2H),2.44(s,3H)。
測試例:生物學評價
測試例1、本發明化合物對腺苷A2a受體(adenosine A2a receptor,A2aR)cAMP訊息傳遞路徑,腺苷A2b受體(adenosine A2b receptor,A2bR)cAMP訊息傳遞路徑,腺苷A1受體(adenosine A1 receptor,A1R)cAMP訊息傳遞路徑和腺苷A3受體(adenosine A3 receptor,A3R)cAMP訊息傳遞路徑抑制活性的測定。
以下方法用來測定本發明化合物對腺苷A2a受體cAMP訊息傳遞路徑,腺苷A2b受體cAMP訊息傳遞路徑,腺苷A1受體cAMP訊息傳遞路徑和腺苷A3受體cAMP訊息傳遞路徑的抑制活性。實驗方法簡述如下:
一、實驗材料及儀器
1.CHO-K1/A2aR細胞(NM_000675.5)或CHO-K1/A2bR細胞(NM_000676.2)或CHO-K1/A1R細胞(NM_000674.2)或CHO-K1/A3R細胞(NM_000677.3)
2.胎牛血清(Gibco,10099-141)
3.博來黴素(Thermo,R25001)或G418(ENZO,ALX-380-013-G005)或嘌呤黴素(Thermo,10687-010)
4.DMEM/F12培養基(GE,SH30023.01)
5.細胞分離緩衝液(Thermo Fisher,13151014)
6.HEPES(Gibco,42360-099)
7.牛血清白蛋白(MP Biomedicals,219989725)
8.咯利普蘭(sigma,R6520-10MG)
9.腺苷脫胺酶(sigma,10102105001)
10.毛喉素(sigma,F6886)
11.2Cl-IB-MECA(Tocrics,1104/10)
12.N6-環戊基腺苷(Tocris,1702/50)
13.平衡鹽緩衝液(Thermo,14025-092)
14.cAMP動態2試劑盒(cAMP dynamic 2 kit)(Cisbio,62AM4PEB)
15.384孔板(Corning,4514)或(Nunc,267462#)
16.乙基咔唑(Torcis,1691/10)
17.PHERAstar多功能酶標儀(Cisbio,62AM4PEB)
二、實驗步驟
2.1腺苷A2a受體
CHO-K1/A2aR細胞用含有10%胎牛血清和800μg/ml博來黴素的DMEM/F12培養基進行培養。實驗時使用細胞分離緩衝液消化細胞,用含有20mM HEPES和0.1%牛血清白蛋白的平衡鹽緩衝液重懸細胞並計數,將細胞密度調整為106個/ml。在384孔板中每孔加入5μl細胞懸液,2.5μl用含有20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的受試化合物,室溫培養30分鐘。每孔再加入2.5μl用含有 20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的乙基咔唑,室溫培養30分鐘。化合物終濃度是:10000,2000,400,80,16,3.2,0.64,0.128,0.0256,0.00512,0.001024nM,乙基咔唑終濃度是20nM。細胞內cAMP濃度使用cAMP動態2試劑盒檢測。用cAMP裂解緩衝液按1:4的比例分別稀釋cAMP-d2和抗cAMP-Eu-穴狀化合物(Anti-cAMP-Eu-Cryptate)。每孔加入5μl稀釋後的cAMP-d2,再加入5μl稀釋後的抗cAMP-Eu-穴狀化合物,室溫避光培養1小時。採用PHERAstar多功能酶標儀讀取HTRF訊號值。用Graphpad Prism軟體計算化合物抑制活性的IC50值,見表1。
2.2腺苷A1受體
CHO-K1/A1R用含有10%胎牛血清和1mg/mlG418的DMEM/F12培養基進行培養。實驗時使用細胞分離緩衝液消化細胞,然後用含有20mM HEPES和0.1%牛血清白蛋白的平衡鹽緩衝液重懸細胞並計數,將細胞密度調整為5×105個/ml。在384孔板中每孔加入12.5μl細胞懸液,6.25μl用含有20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的受試化合物,室溫培養30分鐘。每孔再加入6.25μl用含有20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的毛喉素和N6-環戊基腺苷,室溫培養30分鐘。化合物終濃 度是:100000,10000,1000,100,10,1,0.1和0nM,毛喉素的終濃度是10μM,CPA的終濃度是10nM。細胞內cAMP濃度使用cAMP動態2試劑盒檢測。用cAMP裂解緩衝液按照1:4的比例分別稀釋cAMP-d2和抗cAMP-Eu-穴狀化合物。每孔加入12.5μl稀釋後的cAMP-d2,再加入12.5μl稀釋後的抗cAMP-Eu-穴狀化合物,室溫避光培養1小時。採用PHERAstar多功能酶標儀讀取HTRF訊號值。用Graphpad Prism軟體計算化合物抑制活性的IC50值,見表2。
2.3腺苷A3受體
CHO-K1/A3R用含有10%胎牛血清和10μg/ml嘌呤黴素的DMEM/F12培養基進行培養。實驗時使用細胞分離緩衝液消化細胞,用含有20mM HEPES和0.1%牛血清白蛋白的平衡鹽緩衝液重懸細胞並計數,將細胞密度調整為5×105/ml。在384孔板中每孔加入12.5μl細胞懸液,6.25μl用含有20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的受試化合物,室溫培養30分鐘。每孔再加入6.25μl用含有20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的毛喉素和2Cl-IB-MECA,室溫培養30分鐘。化合物終濃度是:100000,10000,1000,100,10,1,0.1和0nM,毛喉素的終濃度是10μM,2Cl-IB-MECA的終濃度是5nM。細胞內cAMP濃度使用cAMP動態2試劑盒檢測。用cAMP裂 解緩衝液按照1:4的比例分別稀釋cAMP-d2和抗cAMP-Eu-穴狀化合物。每孔加入12.5μl稀釋後的cAMP-d2,再加入12.5μl稀釋後的抗cAMP-Eu-穴狀化合物,室溫避光培養1小時。採用PHERAstar多功能酶標儀讀取HTRF訊號值。用Graphpad Prism軟體計算化合物抑制活性的IC50值,見表2。
2.4腺苷A2b受體(adenosine A2b receptor,A2bR)
CHO-K1/A2bR用含有10%胎牛血清和1mg/ml G418的DMEM/F12培養基進行培養。實驗時使用細胞分離緩衝液消化細胞,用含有20mM HEPES和0.1%牛血清白蛋白的平衡鹽緩衝液重懸細胞並計數,將細胞密度調整為106個/ml。在384孔板中每孔加入5μl細胞懸液,2.5μl用含有20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的受試化合物,室溫培養30分鐘。每孔再加入2.5μl用含有20mM HEPES,0.1%牛血清白蛋白,54μM咯利普蘭和2.7U/ml腺苷脫胺酶的平衡鹽緩衝液配製的4×濃度的乙基咔唑(Torcis,1691/10),室溫培養30分鐘。化合物終濃度是:100000,10000,1000,100,10,1,0.1和0nM,乙基咔唑終濃度是1μM。細胞內cAMP濃度使用cAMP動態2試劑盒檢測。用cAMP裂解緩衝液按1:4的比例分別稀釋cAMP-d2和抗cAMP-Eu-穴狀化合物。每孔加入5μl稀釋後的cAMP-d2,再加入5μl稀釋後的抗cAMP-Eu-穴狀化合物,室溫避光培養1小時。採用PHERAstar多功能酶標儀 讀取HTRF訊號值。用Graphpad Prism軟體計算化合物抑制活性的IC50值。見表3。
結論:本發明化合物對腺苷A2a受體cAMP訊息傳遞路徑具有明顯的抑制活性。
結論:本發明化合物對腺苷A1受體和A3受體抑制活性作用較弱,說明本發明化合物對A2a受體具有高選擇性。
結論:本發明化合物對腺苷A2b受體抑制活性作用較 弱,說明本發明化合物對A2a受體具有高選擇性。
測試例2、本發明化合物小鼠腦通透性的測定
本發明化合物小鼠腦通透性採用如下實驗方法測定:
一.實驗材料與儀器
1.RED裝置(Device Inserts)(Thermo Scientific,QL21291110)
2.API 4000 Q-trap線性離子阱質譜儀(Applied Biosystems)
3.LC-30A超高壓液相層析系統(島津)
4.pH7.4 PBS(100mM,4℃冰箱保存)
5.C57小鼠,由傑思捷實驗動物有限公司提供,動物生產許可證號SCXK(滬)2013-0006。
二.實驗動物操作
C57小鼠4隻,雌性,12/12小時光/暗調節,溫度24±3℃恆溫,濕度50-60%,自由進食飲水。禁食一夜後分別灌胃給藥。給藥劑量20mg/kg,給藥組於給藥後0.5h採血後處死(採血量0.5ml),血樣置於肝素化試管中,3500rpm離心10min分離血漿,記為血漿1,於80℃保存;處死後的動物心臟灌流生理鹽水,去除腦組織中多餘血液,取腦組織,濾紙吸幹殘留的血液,記為腦組織1,80℃保存。另取3隻動物取空白血漿和腦組織2,處理方法同給藥組。
三.血漿蛋白結合平衡透析過程
3.1樣品製備
用DMSO溶解藥物化合物至20mM,得到儲備液I;移取適量儲備液I,用甲醇稀釋得到200μM稀釋儲備液II;移取10μl儲備液II于1.5ml Eppendorf管中,加入990μl空白血漿,混勻得到2μM血漿樣品2(DMSO含量0.2%),用於該濃度血漿蛋白結合率的測定。移取上述配好的50μl血漿樣品,記為T0,置於-4℃冰箱保存待測。
3.2實驗過程
取RED裝置將平衡透析管插至於96孔的底板中。取上述配製好的含待測物血漿樣品2及相應空白血漿樣品300μl,置於紅色標記的孔中(plasma chamber)。取500μl pH 7.4磷酸緩衝鹽溶液,置於並排紅色標記的另一孔中(buffer chamber)。按上述步驟處理方法,每個化合物每一個濃度為2個樣本。完畢用封條(sealing tape)覆蓋96孔板,並將整塊底板放至熱混儀中,以400rpm轉速,於37℃平衡4h。培養結束後,從熱混儀中取出96孔底板裝置,完成平衡透析。取25μl平衡後的血漿樣品或透析液樣品,加入25μl相對應的未平衡的不含藥的空白磷酸鹽緩衝液或不含藥的空白血漿,加入內標(乙腈配製)200μl,渦旋混合5min,離心10min(4000rpm),取上清液進行LC/MS/MS分析。T0樣品不經培養,直接採用上述建立的LC/MS/MS法分別測定總藥物(plasma chamber)及游離藥物(buffer chamber)與內標物層析峰面積比,計算游離百分率(fu plasma%)。
四.腦組織蛋白結合平衡透析過程
腦組織蛋白結合平衡透析過程:空白腦組織2按照稀釋因數=11的比例用pH7.4 PBS將腦組織製成空白腦勻漿,加入化合物配製成2μM腦勻漿,其餘與血漿蛋白結合的操作相同,採用建立的LC/MS/MS法分別測定總藥物(brain homo chamber)及游離藥物(buffer chamber)與內標物層析峰面積比,計算游離百分率(fu brain hom%)。
五.腦通透試驗數據計算方法
5.1採用建立的LC/MS/MS法分別測定小鼠給藥後0.5h的血漿1和腦組織1中的藥物濃度,此為總濃度(Ctotal,p和Ctotal,b);
5.2採用RED Device Inserts裝置,用平衡透析法分別測定化合物在小鼠血漿和腦組織中的蛋白結合率,從而計算出游離百分率(fu plasma%,fu brain%);血漿游離百分率(fu plasma%)Cbuffer/Cplasma×100%;腦勻漿游離百分率(fu brain hom%)=Cbuffer/Cbrain hom×100%;腦組織游離百分率(fu brain%)=fu brain hom/(Df-(Df-1)×fu brain hom)×100%;此處Df=11
5.3採用以下公式計算血腦通透指數Kp-unbound。
六.試驗結果與討論
本發明化合物的腦通透指數如下:
結論:本發明化合物在腦中的游離藥物濃度低,透過血腦屏障能力弱,較少藥物進腦,可能產生的副作用低。
Claims (19)
- 一種通式(I)所示之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,
- 如申請專利範圍第1項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中,該R 2係選自氰基、環烷基、雜環基、芳基和雜芳基;其中,該環烷基、雜環基、芳基和雜芳基各自獨立地視需要經選自鹵素、烷基、鹵烷基、烷氧基、氧代基、環烷基、雜環基和R b中的一個或多個取代基所取代;R b為雜環基烷基,其中,該雜環基烷基中的雜環基視需要經一個或多個烷基所取代。
- 如申請專利範圍第1項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其為通式(II)所示的化合物:
- 如申請專利範圍第1至3項中任一項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其為通式(III)所示的化合物:
- 如申請專利範圍第3或4項所述(II)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中,該環B選自:苯基、吡啶基、吡唑基、吡啶-2-酮基、咪唑基、吡咯基、呋喃基、噻吩基、哌啶基、四氫吡啶基、異喹啉基、喹啉基、喹 啉基、吲哚基、 吲唑基、苯并呋喃基或苯并噻吩基。
- 如申請專利範圍第1至5項中任一項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其為通式(III’)所示的化合物:
- 如申請專利範圍第1至6項中任一項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可 接受之鹽,其中,該環A為芳基或雜芳基。
- 如申請專利範圍第7項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中,該環A為苯基或呋喃基。
- 如申請專利範圍第1至8項中任一項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中,該R 1選自氫原子、鹵素或烷基。
- 如申請專利範圍第1至9項中任一項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其中,該R 3係選自氫原子、鹵素或烷基。
- 如申請專利範圍第1至10項中任一項所述(I)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其係選自:
- 一種通式(IV)所示之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽:
- 如申請專利範圍第12項所述(IV)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,其 中,該化合物係選自:
- 一種製備如申請專利範圍第3項所述(II)之化合物、或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽之方法,該方法包括:
- 一種醫藥組成物,該醫藥組成物含有治療有效量的如申請專利範圍第1至11項中任一項所述之化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式或其醫藥上可接受之鹽,以及一種或多種醫藥上可接受的載體、稀釋劑或賦形劑。
- 一種用途,其係如申請專利範圍第1至11項中任一項所述之化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式、或其 醫藥上可接受之鹽或如申請專利範圍第14項所述之醫藥組成物在製備用於抑制A 2a受體的藥物中的用途。
- 一種用途,其係如申請專利範圍第1至11項中任一項所述之化合物或其互變異構體、內消旋體、外消旋體、對映異構體、非對映異構體、或其混合物形式、或其醫藥上可接受之鹽或如申請專利範圍第14項所述的醫藥組成物在製備用於治療藉由對A 2a受體的抑制而改善的病況或病症的藥物中的用途。
- 如申請專利範圍第17項所述的用途,其中,該藉由對A 2a受體的抑制而改善的病況或病症係選自腫瘤、抑鬱症、認知功能病症、神經退行性病症、注意力相關病症、錐體外症候群、異常運動障礙、肝硬化、肝纖維化、脂肪肝、皮膚纖維化、睡眠障礙、中風、腦損傷、神經炎症和成癮行為。
- 如申請專利範圍第18項所述的用途,其中,該藉由對A 2a受體的抑制而改善的病況或病症為腫瘤。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710156742 | 2017-03-16 | ||
CN201710156742.7 | 2017-03-16 | ||
CN201710982734 | 2017-10-20 | ||
CN201710982734.8 | 2017-10-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201835083A true TW201835083A (zh) | 2018-10-01 |
TWI772386B TWI772386B (zh) | 2022-08-01 |
Family
ID=63523780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107109077A TWI772386B (zh) | 2017-03-16 | 2018-03-16 | 雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11312705B2 (zh) |
EP (1) | EP3575301A4 (zh) |
JP (1) | JP7111733B2 (zh) |
KR (1) | KR20190129851A (zh) |
CN (1) | CN109963854B (zh) |
AU (1) | AU2018233367B2 (zh) |
BR (1) | BR112019017108A2 (zh) |
CA (1) | CA3054976A1 (zh) |
MX (1) | MX2019010354A (zh) |
RU (1) | RU2764655C2 (zh) |
TW (1) | TWI772386B (zh) |
UA (1) | UA125592C2 (zh) |
WO (1) | WO2018166493A1 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
MX2016010390A (es) | 2014-02-13 | 2017-02-27 | Incyte Corp | Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1). |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016161282A1 (en) | 2015-04-03 | 2016-10-06 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
UA126277C2 (uk) | 2015-08-12 | 2022-09-14 | Інсайт Корпорейшн | Солі інгібітору lsd1 |
CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
JP7474709B2 (ja) * | 2018-02-27 | 2024-04-25 | インサイト・コーポレイション | A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン |
WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
AR116315A1 (es) | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
CN110903291B (zh) * | 2018-09-14 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法 |
CN112334473B (zh) * | 2018-09-14 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法 |
CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
WO2020128036A1 (en) * | 2018-12-21 | 2020-06-25 | Ryvu Therapeutics S.A. | Modulators of the adenosine a2a receptor |
MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
CN111848625B (zh) * | 2019-04-24 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 一种杂芳基并[4,3-c]嘧啶-5-胺类化合物的制备方法及中间体 |
WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
KR20230049579A (ko) * | 2020-03-26 | 2023-04-13 | 헵테얼즈 테라퓨틱스 리미티드 | 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 |
WO2021191380A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
CN115867280A (zh) * | 2020-03-26 | 2023-03-28 | 赫普泰雅治疗有限公司 | 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 |
WO2021191376A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE257156T1 (de) * | 1997-03-24 | 2004-01-15 | Kyowa Hakko Kogyo Kk | (1,2,4)triazolo(1,5-c)pyrimidin-derivate |
US6545000B1 (en) * | 1998-09-22 | 2003-04-08 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]triazolo[1,5-c]pyrimidine derivatives |
US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
JP2002037787A (ja) * | 2000-05-16 | 2002-02-06 | Kyowa Hakko Kogyo Co Ltd | [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体の製造法 |
AU2003211993A1 (en) | 2002-02-15 | 2003-09-04 | Kyowa Hakko Kogyo Co., Ltd. | (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES |
KR100968989B1 (ko) * | 2005-03-23 | 2010-07-09 | 에프. 호프만-라 로슈 아게 | mGluR2 길항제로서 아세틸렌일-피라졸로-피리미딘 유도체 |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
DE102006008880A1 (de) | 2006-02-27 | 2007-09-06 | Merck Patent Gmbh | Aminopyrimidinderivate |
WO2007116106A1 (es) | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
DE102007061763A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
EP2262811B1 (en) | 2008-03-04 | 2016-04-27 | Merck Sharp & Dohme Corp. | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
US8796297B2 (en) | 2009-06-30 | 2014-08-05 | Abbvie Inc. | 4-substituted-2-amino-pyrimidine derivatives |
JO3090B1 (ar) | 2009-12-11 | 2017-03-15 | Janssen Sciences Ireland Uc | 5- امينو-4- هيدروكسي-بنتويل اميدات |
AU2011212430B2 (en) | 2010-02-05 | 2014-05-29 | Nxera Pharma Uk Limited | 1,2,4-triazine-4-amine derivatives |
SG185524A1 (en) | 2010-05-12 | 2012-12-28 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
WO2011159302A1 (en) | 2010-06-17 | 2011-12-22 | Janssen Pharmaceutica Nv | Arylindenopyrimidines for treating neurodegenerative and movement disorders while minimizing cardiac toxicity |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
EP2952514A1 (en) | 2010-10-29 | 2015-12-09 | Pfizer Inc | N1/n2-lactam acetyl-coa carboxylase inhibitors |
PL2699575T3 (pl) * | 2011-04-21 | 2015-08-31 | Bayer Ip Gmbh | Triazolopirydyny |
TW201326170A (zh) * | 2011-12-12 | 2013-07-01 | 拜耳製藥公司 | 經取代之三唑并吡啶 |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
TWI628176B (zh) | 2013-04-04 | 2018-07-01 | 奧利安公司 | 蛋白質激酶抑制劑 |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
WO2015193263A1 (en) | 2014-06-17 | 2015-12-23 | Chiesi Farmaceutici S.P.A. | Indolizine derivatives as phoshoinositide 3-kinases inhibitors |
RS58679B1 (sr) * | 2014-12-23 | 2019-06-28 | Novartis Ag | Triazolopirimidin jednijenja i njihova upotreba |
CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
JP7474709B2 (ja) * | 2018-02-27 | 2024-04-25 | インサイト・コーポレイション | A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン |
-
2018
- 2018-03-15 US US16/492,273 patent/US11312705B2/en active Active
- 2018-03-15 BR BR112019017108A patent/BR112019017108A2/pt not_active Application Discontinuation
- 2018-03-15 EP EP18766881.9A patent/EP3575301A4/en not_active Withdrawn
- 2018-03-15 MX MX2019010354A patent/MX2019010354A/es unknown
- 2018-03-15 AU AU2018233367A patent/AU2018233367B2/en not_active Ceased
- 2018-03-15 CA CA3054976A patent/CA3054976A1/en active Pending
- 2018-03-15 RU RU2019131111A patent/RU2764655C2/ru active
- 2018-03-15 WO PCT/CN2018/079086 patent/WO2018166493A1/zh unknown
- 2018-03-15 CN CN201880004302.2A patent/CN109963854B/zh active Active
- 2018-03-15 JP JP2019548401A patent/JP7111733B2/ja active Active
- 2018-03-15 UA UAA201910243A patent/UA125592C2/uk unknown
- 2018-03-15 KR KR1020197025674A patent/KR20190129851A/ko not_active Application Discontinuation
- 2018-03-16 TW TW107109077A patent/TWI772386B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
UA125592C2 (uk) | 2022-04-27 |
TWI772386B (zh) | 2022-08-01 |
RU2019131111A (ru) | 2021-04-16 |
JP7111733B2 (ja) | 2022-08-02 |
US20210032224A1 (en) | 2021-02-04 |
BR112019017108A2 (pt) | 2020-04-07 |
RU2019131111A3 (zh) | 2021-04-16 |
CA3054976A1 (en) | 2018-09-20 |
AU2018233367B2 (en) | 2021-08-12 |
WO2018166493A1 (zh) | 2018-09-20 |
KR20190129851A (ko) | 2019-11-20 |
AU2018233367A1 (en) | 2019-08-29 |
JP2020510012A (ja) | 2020-04-02 |
EP3575301A4 (en) | 2020-08-05 |
CN109963854B (zh) | 2022-04-12 |
RU2764655C2 (ru) | 2022-01-19 |
EP3575301A1 (en) | 2019-12-04 |
MX2019010354A (es) | 2019-10-22 |
US11312705B2 (en) | 2022-04-26 |
CN109963854A (zh) | 2019-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI772386B (zh) | 雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用 | |
CN108884061B (zh) | 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 | |
CN109535161B (zh) | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
TWI662026B (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
WO2017084494A1 (zh) | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 | |
TWI701251B (zh) | 吡唑并[1,5-a][1,3,5]三-2-胺類衍生物、其製備方法及其在醫藥上的應用 | |
TW201910329A (zh) | 取代五元并六元雜環類化合物、其製備方法、藥物組合及其用途 | |
EA025863B1 (ru) | Карбазолкарбоксамидные соединения | |
WO2020011220A1 (zh) | 杂芳基类衍生物、其制备方法及其在医药上的应用 | |
TW201835079A (zh) | 6-吡唑-[1,2,4]三唑並[4,3-α]吡啶-3-醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
CN108467386B (zh) | 稠杂芳基取代的1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 | |
WO2022089219A1 (zh) | 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途 | |
CN115340559A (zh) | Shp2磷酸酶杂环类抑制剂的制备及其应用 | |
WO2020156505A1 (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
CN110684020B (zh) | 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
CN110655509B (zh) | 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
WO2024114680A1 (zh) | 杂环化合物、药物组合物及其应用 | |
WO2024114680A9 (zh) | 杂环化合物、药物组合物及其应用 | |
TW202334140A (zh) | 作為骨髓細胞上表現之觸發受體2促效劑之雜環化合物及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |